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Abstract: E3 protein from vaccinia virus is a key host-range protein, which suppresses the 
innate antiviral immune response of the infected cells. In response to the viral infection, 
Protein Kinase R (PKR) of the host cell initiates the immune response via a cascade of 
reactions. E3 attacks PKR to suppress the immune response, but the mechanism of PKR 
inhibition by E3 is unknown. In this study, it was found that the kinase domain of PKR 
had a physical interaction with E3 that has biochemical relevance. E3 follows two 
different pathways when inhibiting inactivated and activated PKR-KD. E3 binds to 
monomeric PKR-KD inhibiting its phosphorylation by forming an inactive heterodimer, 
which eventually leads to disruption of immune response via PKR in host cells. The 
mechanism of E3 inhibition of dimeric PKR-KD is unknown but the data suggests a weak 
interaction between the proteins leading to disruption of PKR activity. The study also 
detailed the importance of both N and C terminals of E3 for PKR inhibition. Further 
analysis of the interaction revealed that the inhibition of PKR-KD activation by E3 
protein does not correlate with the dsRNA binding ability of PKR or E3.   
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Traditionally, vaccinia virus (VACV) has been used as vaccination against small 
pox. VACV is a large DNA virus that has the ability to replicate in the cytoplasm of the 
infected cells unlike other viruses [1]. It was used as a vaccine to eradicate small pox 
successfully. Although the vaccination for small pox has been discontinued for general 
public, certain military organization in the United States continue to vaccinate owing to 
the threat of small pox used as a bioterrorism agent [2]. Immune-challenged individuals, 
newborns, pregnant women and older people who come in contact with VACV viruses 
might develop complications, that are in some cases fatal [2]. Hence, there has been a 
greater need to study recombinant vaccinia viruses that would have familiar advantages 
of smallpox vaccine i.e. heat stability, low cost and ease of administration [3]. Not only 
for smallpox, but VACV has also been actively researched for development of 
recombinant vector viruses for immunization against other infectious diseases. The wide 
host range of VACV allows the development of recombinant vectors that could be used 
against infectious agents in a variety of experimental animals from rodents to primates 
[3]. An example of VACV developed for treating other diseases is the development of an 
AIDS vaccine that have led to the human testing of a first-generation recombinant VACV 





VACV encodes a number of host range genes and among them the most studied is the 
E3L gene that produces E3 protein.  E3 protein is composed of 190 amino acids and 
comprises of two domains. The N-terminal contains a Z-DNA binding domain (ZBD) that 
binds to Z-form DNA. The C-terminal domain contains a dsRNA binding domain (DRBD) 
and binds to dsRNA produced during viral infection [6, 7]. The best characterized biological 
functions of the E3 protein includes its host range function, suppression of cytokine 
expression, and inhibition of interferon (IFN)-induced antiviral activity [8-10]. E3 protein 
suppresses the antiviral immune response of the host cells by blocking multiple immune 
response pathways. Of the number of ways, Protein Kinase R (PKR) is the most notable 
immune response protein that are affected by E3 (Fig. 1-1). Mammalian PKR is a double-
stranded RNA dependent protein kinase that is transcriptionally induced by interferon and 
becomes activated in virus-infected cells by dsRNAs produced during the virus life cycle [11, 
12]. There are two contradictory models that have been put forward regarding the 
biochemical capacity of E3 proteins to bind to dsRNA and their ability to suppress the innate 
immune response via PKR response pathway. It has been shown that E3 inhibits PKR by a 
novel mechanism in which the inhibitory E3 N-terminal domain is tethered to and inhibit the 
kinase domain of PKR, in association with the dsRNA binding motifs (DRBMs) of the two 
proteins mediated through dsRNA binding [13]. But an opposing model suggests that the 
dsRNA binding capability of E3 protein is not essential for its activity of inhibiting PKR 
[14].  
Understanding the mechanism of E3 inhibition of PKR activity could be the key to 




including smallpox. The global immunity to smallpox has declined significantly due to the 
cessation of  mass vaccination in the 1970s. Since there is no treatment for smallpox other 
than vaccination in the form of attenuated live vaccines, development of other forms of 
treatments are of the greatest importance.  
 
                                
                       
Figure 1.1. E3 suppression of host immune system.  
E3L of VACV evades the IFN system by blocking IFN induction through IRF3 and IFN 







1.2. Research Goals and Overview 
My doctoral research has primarily focused on the mechanistic studies of vaccinia E3 
protein and its inhibitory effect on the activity of mammalian PKR. Structural and functional 
approaches were directed to achieve this aim (Fig. 1.2). Efforts were made to attain stable 
and homogenous E3 protein which were used for understanding structure of the protein by x-
ray crystallography. Functional studies were conducted to understand the protein-protein 
interactions between E3 and PKR.  
A major gap in the knowledge of E3 is the absence of structure of E3 protein. E3 
remains in an aggregated state in cytoplasm of host cells. A study reported that wildtype E3 
proteins expressed in bacterial systems and purified in buffer containing 1M NaCl existed in 
a dimeric form. Although, the E3 protein remained as a dimer at a high ionic strength buffer, 
it was suggested that oligomerization of E3 also depended on concentration of protein [16]. 
The idea of using protein engineering to alleviate aggregation towards structural studies is 
enlightened from a recent success on a non-related difficult protein project conducted by a 
group in Baylor College of Medicine, Texas [17].  NS1 protein from H5N1 influenza virus 
suppresses antiviral interferon (IFN) induction in the host cells but how the protein 
antagonizes the IFN response was unknown [18]. NS1 protein remains in an aggregated form 
in the cytoplasm of the host cell similar to E3. Aiming to solve the atomic structure of NS1 
by crystallography, the group performed a series of single point mutations where they 
determined two single mutations that completely removed aggregation. The approach 
allowed them to crystallize the NS1 protein and perform structural analysis of the crystal 




mitigate the problem of aggregation and thus help in the structural studies of this protein 
through x-ray crystallography.   
This study also aimed at defining the physical and functional characteristics of 
protein-protein interactions between E3 and PKR. It is well known that E3 suppresses the 
activation of PKR by physically interacting with the full length PKR both in vivo and in 
vitro. Based on a recent study, it was found that the binding of E3 to PKR does not require 
dsRNA binding capacity to the dsRNA as suggested in a previous model [14]. In this study, 
we predicted that E3 and the kinase domain of PKR would physically interact to form an 
inactive complex that leads to the inhibition of PKR activity. It was also predicted that the 
dsRNA binding abilities was dispensable for the interaction between these proteins.  
 
 
Figure 1.2. Various approaches were followed for conducting mechanistic studies on E3 
protein.   





REVIEW OF LITERATURE 
 
2.1. Introduction 
Poxviruses comprise a large family of viruses that infect a wide variety of 
vertebrate and invertebrate hosts [19]. These viruses are a diverse family of double-
stranded DNA viruses which replicate exclusively in the cytoplasm of infected cells and 
exhibit a varied host range [20]. Poxviruses include many important human and animal 
pathogens such a variola virus, the causative agent of smallpox. Another important 
member of this family is the VACV which was successfully used for the prevention and 
the eradication of smallpox [1].  
Unlike variola virus that has a specific host, VACV displays a broad host range 
and encodes a number of immunomodulatory proteins such as host range proteins [21]. 
Of the 200 genes encoded by VACV, one-third are dedicated to host immune evasion 
[22]. Some examples of host range genes include SPI-1, K1L, C7L, p28/N1R, B5R, K3L, 
and E3L, the alteration or deletion of which restricts the virus replication in specific cell 
lines [8]. These host range genes encode for proteins that perform specific biological 
functions within the host cell in response to viral infections. This section of the chapter 
focuses on the E3 protein, its physical and chemical characteristics, functions and 






2.2. VACV E3 protein 
E3 is an extensively studied vaccinia host range protein, which is expressed early in 
the viral replication cycle. It is a prototypic member of the orthopoxviruses and functions as 
an inhibitor of innate immune signaling and also essential for vaccinia virus replication in 
vivo in many human cell culture systems [23]. It is a highly conserved protein in VACV and 
E3 orthologues present in other poxviruses such as sheeppox virus, yaba monkey tumor 
virus, swinepox virus, myxoma virus, are relatively conserved but with comparatively less 
sequence conservation (Fig. 2.1). These E3 orthologues could partially complement 
important functions of E3, including suppression of PKR activation, cytokine expression and 
inhibition of the antiviral effects of IFN in vivo but, none of the E3 orthologues were able to 
restore pathogenicity in E3 protein deficient vaccinia virus [23].  
Many studies over the past 15 years have clearly demonstrated E3 as a host range 
protein, required for VACV replication in many cell lines [8]. An E3 protein deleted VACV 
strain resulted in the inhibition of viral and cellular protein synthesis and reduced viral 
replication which was reverted by transient transfection of E3 [24]. In another study, E3 
deleted VACV was unable to replicate productively (because of termination at the level of 
late gene expression) in a murine epidermis-derived dendritic cell line XS52 [25]. In the 
same study, it was observed that XS52 cell line that had infection with VACV lacking E3 
resulted in activation of NF-kB and production of proinflammatory cytokines like TNF and 
IL-6 [25]. Many studies have focused on E3 in terms of defining the mechanism of evasion 
of host defenses such as in a study it was found that expression of E3 in cell lines interferes 




apoptosis, and impairment of antiviral activity [26]. It was observed that mouse NIH3T3 
mammalian cells expressing E3 protein, inhibited eIF-2a phosphorylation and initiated 
IkBa degradation in response to dsRNA along with resistance to dsRNA-triggered apoptosis 
[26].  
               
 
 
Figure 2.1. E3 and E3 orthologues sequence alignment.  
E3 orthologues are early genes whose protein products display significant amino acid 
divergence. Protein sequence alignments were generated using the CLUSTALW OMEGA 
program. The “.” symbol denotes semiconserved substitutions, the “:” symbol denotes 
conserved substitutions, and the “*” symbol denotes complete conservation of the residue 
across all sequences. The amino acids highlighted in red indicate residues previously 
identified to contribute to E3 dsRNA binding. Figure adapted from reference [23].  
 
 
E3          MSK-IYIDERSDAEIVCAAIKNIG-IEGATAAQLTRQLNMEKREVNKALYDLQRSAMVYS 58 
M029        -----------------------------------------------------------M 1 
SPV032      --MCSDISNEDVYSLVKQEVDSLPVGNFITAVEISKKIEKEKSSINRQLYALYQQGYIDM 58 
SPPV34      --MYS-CDEVDSYELVKKIVNNLSESESITAIEISKKLNIEKSNVNKQLYKLHNDGFIFM 57 
YMTV34      MDSPGCENDVKTFSLVKNEVMMLNVDEYTTSIDISNKLKINKKKINKQLYKLQKEGVLKM 60 
                                                                         
 
E3          SDDIPPRWFMTTEADKPDADAMADVIIDDVSREKSMREDHKSFDDVIPAKKIIDWKDANP 118 
M029        DPI-NTLWHNALS-----------------SGNAAVSETKPIFGDTIKYEKIVSWQTKNP 43 
SPV032      VPACPPKWYKRNQDN-----M--------NNESIEIHNPDHMFSDTIPYTKIIEWKNKNP 105 
SPPV34      IRSNPPKWFKKNGIDNDDNEN--------NN----TKKLNKSFSDTIPYYKIVLWKEKNP 105 
YMTV34      VPSNPPKWFKNCNCEDSENND--------NKLESRDHVPHHIFKDEIPYKKIISWKDKTP 112 
                   *.                     .        .  * * *   **: *:  .* 
 
E3          VTIINEYCQITKRDWSFRIESVGPSNSPTFYACVDIDGRVFDKADGKSKRDAKNNAAKLA 178 
M029        CTVLNEYCQITFREWSINVTRAGQSHSPTFTAVVTVSGYSFKSATGSNKKEARKNAAKEA 103 
SPV032      ITVLNEYCQITQRDWIIDIISSGQSHCPIFTASITVSGIKCKTGKGSTKKEAKQIAARET 165 
SPPV34      CSAINEYCQFTSRDWYINISSCGNGRKPMFLASVIISGIKFFPEIGNTKKEAKQKSTKRT 165 
YMTV34      CTVINEYCQLTSRDWSIEVTTAGESHCPIFTASVIISGIKFKPEIGNTKKEAKHKASKIT 172 
             : :*****:* *:* : :   * .. * * * : :.*       *..*::*:: ::: : 
 
E3          VDKLLGYVIIRF 190 
M029        MDVILKHVVIKF 115 
SPV032      MNFILNKTIIKF 177 
SPPV34      IDFLINTSIIKF 177 
YMTV34      MEEILKSSIVKF 184 





E3 protein consists of two conserved domains that are essential for pathogenesis [27]. 
Limited proteolysis of the E3 protein have shown the presence of two trypsin-resistant 
structural domains separated by a protease-sensitive interdomain bridge [16] (Fig. 2.2). The 
C-terminal double stranded RNA binding domain (DRBD) functions by sequestering dsRNA 
to avoid activation of IFN-inducible, dsRNA-dependent antiviral enzymes such as PKR [24, 
27-29]. The N-terminal domain has a Z-DNA binding domain whose function is not well 
understood. It was found that the amino terminal domain was not necessary for viral 
replication but was required for pathogenicity in vivo [30]. The N-terminal contributed to 
neurovirulence of the virus [28]. It was observed in a study that pathogenesis in N-terminal 
mutants of VAVC E3 correlated with binding to Z-DNA in vitro and in vivo [31]. The N-
terminus was found to be important for inhibiting PKR-dependent IFN in mouse embryonic 
fibroblasts (MEFs) [31]. Previous studies have revealed the Z-DNA binding activity of E3 is 
critical for viral pathogenesis but it was recently found that in variola virus E3 protein, its Z-
DNA domain is required rather than its Z-DNA binding activity, for PKR inhibition [32]. 
 
           
Figure 2.2. The domain structure of E3 protein with a N-terminal Z-DNA binding domain 
and a C-terminal dsRNA-binding domain separated by a protease-sensitive interdomain 
bridge.   
 
E3 protein is an extensively studied protein but understanding its structure has been 




orthologues. The crystal structure of the Z-DNA binding domain from the E3-like protein of 
Yaba-like disease virus, a Yatapoxvirus, in complex with Z-DNA was solved at 2.0 Å 
resolution (Fig. 2.3). The crystal structure of yabZαE3L has an α/β architecture, consisting of 
three β-strands and three α-strands. The three α helices (α1, α2, and α3) form a core domain, 
which is flanked by a β-sheet of three antiparallel strands (β1, β2, and β3). α2, and α3 form 
an helix-turn-helix motif and two antiparallel β-strands (β2 and β3) form a wing [33].  
            
 
Figure 2.3. Crystal structure of Z-DNA binding domain of E3 orthologue.  
The overall structure of the yabZαE3L:Z-DNA complex. The N and C terminus and 
secondary structure elements are labeled. Figure adapted from reference [33]. Figure 
generated by The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC. 
 
 
The biological functions of VACV E3 protein such as host range function and 
inhibition of innate immune responses are known to be primarily mediated through the 
DRBD of E3 protein. It functions through sequestering virus-produced dsRNA in host cells 




oligoadenylate synthase [6, 27, 36]. In an E3 protein deleted VACV strain, an inhibition of 
viral and cellular protein synthesis and reduced viral replication was observed [24]. The viral 
replication was restored by transient transfection of E3 and was shown that the C-terminal 
domain of E3 was important for the rescue [24]. The nonessential nature of E3 N-terminal 
was detected for viral infection in cell cultures whereas the absolute requirement of both 
domains for full pathogenesis was observed in mice [28]. A recent study was conducted to 
better understand the biological relevance of dsRNA binding ability of E3. It was found that 
the dsRNA binding abilities of E3 was not essential for its biological functions [14]. This 
study involved a series of E3 mutants that were evaluated for dsRNA binding capacity and 
expression of host range functions (Table 2.1). It was also reported in this study that the 
domains of E3 required for biological functions overlap the domains critical for its 





Table 2.1. Amino acids of E3 protein critical for dsRNA binding and host range       
                          
Note: Table adapted from reference [14] 
 
2.3. Protein Kinase R. (PKR) 
PKR belongs to the family of protein kinases, which include other kinases such as 
HRI, PERK, GCN2 and collectively constitute a functional family called the eIF2a protein 
kinases. PKR is a soluble protein rich in serine and threonine. It is constitutively expressed in 
most mammalian cell types. PKR is induced by type I interferons and plays an important role 




viral infections, pathogen associated molecular patterns (PAMPs) in the form of nucleic acids 
are produced in the host cell [38, 39]. These dsRNAs produced during viral infections lead to 
PKR activation. Activated PKR then leads to inhibition of protein synthesis and apoptosis 
[40]. PKR is also involved in stress responses, inflammation pathways, regulates cellular 
growth and proliferation, nutrient signaling and metabolism [41-43].  
Human PKR is a 551 amino acid protein and consists of two distinct domains. The N-
terminal (amino acids 1-170) has two DRBDs of approximately 65 amino acid residues each, 
separated by a 20 amino acid linker [44]. The structure of PKR N-terminal domain was 
solved using NMR and each DRBD consists of an a-b-b-b-a conformation (Fig. 2.4). The 
flexible 20 amino acid linker found between the two DRBDs in the N-terminal consists of 
random coil conformation and binds around the dsRNA helix for optimal interactions [40].  
                                              
   
Figure 2.4. Structure analysis of N-terminal domain of PKR.  
An NMR solution structure of the DRBD of human PKR, comprising two tandem-linked 




reference [40]. Figure generated by The PyMOL Molecular Graphics System, Version 2.0 
Schrödinger, LLC. 
 
The C-terminal domain of PKR (amino acid 258-551) serves as the catalytic domain 
(also known as the kinase domain). It consists of a typical bilobal architecture of a smaller N-
terminal lobe (N-lobe) and a larger C-terminal lobe (C-lobe) as in other protein kinases [45]. 
The structure of kinase domain of PKR was solved by x-ray crystallography in a complex 
form with its substrate eIF2a [45]. Amino acids 258-369 cover the smaller N-lobe of the 
kinase domain that consists of a twisted five-strand antiparallel b sheet (b1 to b5), a 
canonical helix aC laterally flanking one side of the b sheet, and a noncanonical helix a0 
which integrates into the top groove of the b sheet. Amino acids 370-551 form the larger C-
lobe of kinase domain and comprises two paired antiparallel b strands (b7-b8 and b6-b9) and 
eight a helices (aD to aJ) (Fig. 2.5). The active site of the PKR kinase domain occurs in a 
cleft between the N and C-lobes of the domain [45]. A sub-element of the activation site, 
termed as the P+1 loop, is notable for defining Serine/Threonine kinase specificity. This P+1 
loop provides a docking site for the phosphoacceptor sequence of the substrate in the 
immediate vicinity of the active site [46]. The crystal structure solved detected the presence 
of threonine at position 451 of the P+1 loop, which best characterized function of PKR as a 
Serine/Threonine directed protein kinase [45]. The crystal structure shown in figure 2.5 is a 
complex of PKR kinase domain and its substrate eIF2a. The structure indicates a 
phosphorylated threonine 446 residue and adopts a fully structured winding conformation 






Figure 2.5. Structure of the PKR-eIF2α complex.  
Cartoon representation of the PKR/eIF2α complex (P3221 crystal form) highlighting 
catalytic-domain dimerization mediated by the N lobe of PKR and eIF2α recognition 
mediated by the C lobe of PKR. Figure adapted from reference [45]. Figure generated by 
The PyMOL Molecular Graphics System, Version 2.0 Schrödinger, LLC.    
 
2.4. Eukaryotic Translation Initiation Factor (eIF2a) 
Translation of an mRNA molecule by the ribosome occurs in three stages: initiation, 
elongation, and termination. Initiation starts when the small ribosomal subunit binds to the 
start of the mRNA sequence. A transfer RNA (tRNA) molecule carrying the amino acid 
methionine (Met-tRNAi) binds to the start codon (AUG) of the mRNA sequence. This 
complex joins the 60S ribosomal subunit to form an 80S initiation complex. Each of these 
steps is stimulated by soluble protein factors known as eukaryotic initiation factors 
(eIFs). The primary role of eIF2 during the initiation process is to transfer Met-tRNAi to the 




eIF2 and GTP and is stimulated by other translation initiation factors such as eIF3, eIF1A, 
and possibly eIF5B [48, 49]. The resulting 43S preinitiation complex binds mRNA, forming 
the 48S complex, led by the mRNA-associated factors (eIF4E, eIF4G, eIF4A, eIF4B, and 
poly[A]-binding protein) and the eIF3 present in the 43S complex. The preinitiation complex 
scans the mRNA, pairs the anticodon of Met-tRNAi and the AUG start codon triggers 
hydrolysis of GTP by eIF2, dependent of the GTPase activating protein (GAP) eIF5. After 
release of eIF2–GDP and eIF3, the 60S subunit joins the assembly in a reaction stimulated by 
eIF5B and involves the hydrolysis of a second molecule of GTP [49, 50]. The eIF2-GDP 
complex does not bind to the Met-tRNAi, and recycling of the GTP necessitates the guanine 
nucleotide exchange factor (GEF) eIF2B [51].  
eIF2 is a multifunctional protein with three subunits: eIF2a, eIF2b and eIF2g. Both 
the eIF2b and eIF2g subunits are involved in the GTP binding during initiation of translation 
whereas the eIF2a subunit is a major site of control of the translation initiation process 
through the phosphorylation of a specific serine residue (Serine 51) [49, 52]. These subunits 
of eIF2 are well conserved in eukaryotes, homologues of these subunits are present in the 
archaea but not in bacteria [53]. eIF2a acts as a substrate to a number of protein kinases such 
as HRI (Heme regulated protein kinase), PKR (response to dsRNA in viral infected cells), 
GCN2 (response to amino acid starvation) and PERK (response to unfolded proteins in the 
endoplasmic reticulum) [54-58].  
eIF2a is a protein with 303 amino acids and has an elongated two domain structure. 
The structure of N-terminal two-thirds of the human eIF2a was solved by x-ray 
crystallography [59]. The crystal structure revealed a two domain structure where the N-




residues 90-175 form a helical domain [53, 59] (Fig. 2.6). The connectivity of the strands 
within the b-barrel conforms to the OB (oligonucleotide-binding) fold [53, 60]. The structure 
of the same amino acid residues of yeast eIF2a was solved in a different study [53]. The 
structures of both human and yeast eIF2a were compared and was found to have extensive 
similarities but also some significant differences. The disulfide bridge between cysteine 
residue 69 and 97 found in human eIF2a is substituted with a hydrophobic interaction 
between valine residue 69 and cysteine 97 in case of the yeast protein. A four residue 
deletion between helices a1 and a2 of the helical domain and another four residue deletion 
between a3 and a4 helices in the yeast eIF2a are different in comparison to the human 
protein [53]. The other big difference in the crystal structure of yeast and human protein is 
the visibility of the surface loop consisting of residues 51-65 (connecting strands b3 and b4 
of the N-terminal b-barrel domain) in the yeast eIF2a structure. This loop contains the 




                     
 
Figure 2.6. Overall structure of human eIF2α.  
The phosphorylation site (Ser-51) is indicated. The RNA binding site is constituted by the b- 
sheets (purple). Figure adapted from reference [59].  Figure generated by The PyMOL 
Molecular Graphics System, Version 2.0 Schrödinger, LLC. 
 
Another study on the structure of yeast eIF2a1_175 was published where the 
eIF2a was in a complex with dimeric human PKR protein.  It was found that except for the 
region surrounding the serine 51 phosphoacceptor site, the structure of the eIF2a-PKR 
complex was identical to the crystal structure reported earlier for the yeast eIF2a protein 




                                                                  
 
Figure 2.7. Crystal structure of the N-terminal of yeast eIF2α.  
A diagram showing residues 1–175 of the yeast eIF2α structure, indicating the positions of 
some of the conserved side-chains in the vicinity of Ser51 (S51, R52, R53, R54, R56, K60, 
K86, R87). Figure adapted from reference [53]. Figure generated by The PyMOL Molecular 
Graphics System, Version 2.0 Schrödinger, LLC. 
 
2.5. PKR phosphorylates eIF2a to inhibit protein synthesis  
There are three steps involved in PKR inhibition of protein synthesis that starts with 
PKR activation in which the kinase domain dimerization facilitates activation-segment 
autophosphorylation, which in turn promotes the specific recognition of eIF2a substrate. The 
phosphorylated eIF2a then leads to inhibition of protein synthesis.  
In the event of viral infection, PKR initiates a cascade of reactions that initiate 
immune response against the virus.  PKR exists as an inactive monomer in homeostasis but 
undergoes dimerization for its activation during viral infections. Multiple studies have 
proposed an autoinhibition model for PKR activation where dsRNA produced by viruses 




helps in dimerization of the protein [61-63]. Another study supported this autoinhibition 
model by proposing that PKR’s second DRBD interacts with residues within the insert region 
(residues 328-335) to mask PKR’s kinase domain [64]. Although it has been shown that 
dsRNA binding to DRBDs leads to PKR dimerization, evidence for a dsRNA independent 
mechanism also has been reported [65, 66]. A study conducted by Tan et al. found that PKR 
could dimerize in vivo and in vitro independently of the DRBDs and the dimerization in this 
case was mediated by amino acid residues 244 to 296 [67]. A model for PKR dimerization 
was predicted based on these findings suggested the interaction of dsRNA with the DRBDs 
of PKR functions in two ways. In the 1st method, dsRNA binding targets PKR to ribosomes 
that increases the effective intracellular PKR concentration leading to dimerization and 
subsequent functional activity. Whereas in the 2nd method, the dsRNA binding leads to a 
conformational change in PKR that exposes the amino acids 244-296 region to promote 
formation of a PKR homodimer of the kinase domain (Fig. 2.8) [67]. The importance of 
amino acids 244-296 for PKR dimerization was verified by Tan et al. where a cellular 
inhibitor P58IPK binding to these residues altered the conformation of PKR kinase domain in 
such a way that even in the presence of DRBDs, PKR could no longer form a functional 
dimer [67]. Similarly, a study conducted by Romano et al. suggested that the N-terminal of 
VACV E3 protein interacted with the kinase domain of PKR and prevented dimerization via 





             
 
 
Figure 2.8. Proposed model for the modulation of PKR dimerization.  
The catalytic domain (C) and the regulatory domain (R) containing DSRMs are shown. (I) 
dsRNA binding to the DSRMs bridges PKR molecules and induces a conformational change 
that unmasks the dimerization site with residues 244 to 296 (darkened region) to promote 
intermolecular association of PKR. (II) Binding of P58IPK to the aa 244-to-296 region leads 
to monomerization of PKR and presumably to inactivation of the kinase. (III) Deletion of the 
DSRM sequences results in a conformational alteration exposing this dimerization region, 
and thus the isolated catalytic domain is still capable of forming dimers via aa 244 to 296. 
Figure adapted from reference [67].  
 
Based on the crystal structure of the dimeric kinase domain of PKR and eIF2a 
complex, it was observed that the residues on one face of N-lobe in the kinase domain are 
critical in forming the interface between monomers in active PKR dimers. This dimer 
interface orients the two kinase domains in a parallel, back-to-back manner with the PKR 
active sites facing outward [45]. Dimerization of PKR is followed by autophosphorylation 
and the back-to-back conformation of PKR kinase domain dimer makes transphosphorylation 




another dimer in close proximity [45]. Based on these findings another model for PKR 
activation was suggested and is shown in Figure 2.9.  
The second step for PKR activation is autophosphorylation, which occurs 
simultaneously during dimerization. A study showed that a kinase dead PKR mutant K296R 
impaired PKR-KD dimerization, indicating that kinase domain dimerization promotes 
activation segment autophosphorylation of PKR, which in turn would stabilize dimerization 
[68]. Hence, it is considered that autophosphorylation and dimerization are mutually 
protected events. The activation segment which serves the phosphoregulatory function in 
PKR is located between helices aE and aEF in the lower catalytic lobe (residues 432-458) 
[46, 47].   Phosphorylation of certain residues within the activation segment is essential for 
PKR activity. Threonine 446 in the activation segment of PKR kinase domain undergoes 
phosphorylation and known to be critical for general activation of PKR catalytic efficiency, 
for stabilization of the PKR-KD dimer, and for eIF2a specific substrate recognition [13, 45, 
68].  The 2nd threonine residue at 451 position in the activation segment also plays a major 




                        
 
Figure 2.9. Model of PKR activation.  
An inactive, unphosphorylated PKR monomer is activated by binding to dsRNA. Binding of 
activating ligands at the N-terminus of the kinase disrupts an autoinhibitory conformation to 
enable association between monomers and binding of ATP within the catalytic site of the 
kinase domain. Each monomer is autophosphorylated to form the fully active, dimeric 
enzyme. The autophosphorylated dimer dissociates from the activating ligand and binds to 
and phosphorylates protein substrates, exemplified by eIF2α. Figure adapted from reference 
[69].  
 
The third step of PKR activation is the substrate phosphorylation of eIF2a. The 
phosphorylation of eIF2 by PKR kinase domain occurs at a specific residue, Serine 51. The 
crystal structure of PKR-KD and eIF2a complex indicates that eIF2a binds to the C-lobe of 




KD, eIF2a utilizes the surface of its b barrel which involves all the five b-strands [45]. 
Comparison of the crystal structure of eIF2a with PKR-KD-eIF2a complex structure 
revealed that binding of PKR to eIF2 promoted the unfolding of helix insert of eIF2a which 
made the serine 51 site fully accessible to the phosphoacceptor binding site of PKR.  
During the translation initiation process, prior to binding Met-tRNAi, the GDP bound 
to eIF2 must be exchanged for GTP. The exchange of GDP to GTP is mediated by eIF2B 
[70]. Phosphorylation of the conserved serine residue (Ser51) in eIF2α converts eIF2-GDP 
from a substrate to a competitive inhibitor of eIF2B [49]. Due to the increased affinity of 
eIF2 to its enzyme eIF-2B, a high sequestering interaction is formed between the two 
proteins, which inhibits the recycling of GTP to GDP. In order for the translation initiation 
process to start again eIF2a needs to form a complex with GTP which is impossible with the 
dead-end complex of eIF2 and eIF-2B thus blocking the initiation of translation and leading 





                       
    
Figure 2.10. Stress response pathway for regulation of translation by eIF2α phosphorylation.   
The eIF2α kinases phosphorylate eIF2α leading to inhibition of eIF2B (red bar). This results 
in low levels of ternary complex (grey arrow) resulting in reduced general translation (grey 
arrow) and increased translation of GCN4, ATF4, or certain isoforms of C/EBP (black 
arrow). Increased production of the transcription factors GCN4, ATF4, or C/EBP results in 
increased expression of their target genes (green arrow). Figure adapted from reference 
[71]. 
 
2.6. E3 inhibits the activation of PKR  
Activated PKR phosphorylates its substrate, eIF2a, and in turn the phosphorylated 
eIF2a inhibits protein synthesis during viral infections. These reactions are initiated by PKR 
activation as a host immune defense system against viruses. VACV E3 protein, produced 




immune response [72]. E3 downregulated the host defense mechanisms which correlated 
with the accumulation of E3 early in VACV infection [29, 73]. An early study on vaccinia 
virus had reported an inhibitor of PKR autophosphorylation but it the involvement of E3 was 
not specified [74]. E3 is known to bind physically with PKR. Based on in vitro and in vivo 
binding assays in a study conducted by Sharp et al, two regions on PKR were known to 
interact with VACV E3 protein. One of the binding regions involved the DRBDs of PKR and 
the other overlaps the region of interaction with eIF2a and the pseudosubstrate VACV K3 
protein [75].  This study demonstrated that E3 could directly interact with PKR and 
suggested that E3 downregulates PKR by forming nonfunctional heterodimers. These 
nonfunctional heterodimers could prove essential for controlling the activation of PKR 
through other cellular mechanisms such as heparin, which is a known activator of PKR and 
can substitute dsRNA for autophosphorylation of PKR kinase domain [76]. A model 
proposed by Sharp et al. explained the regulation of PKR activity by E3 (Fig. 2.11). PKR 
remains in a latent inactive state in homeostasis. In the advent of viral infection and a low 
concentration of dsRNA in the cell, activates PKR by undergoing dimerization. E3 protein 
produced early in the viral replication cycle binds to the catalytic domain of PKR for 
inhibiting its activation, in the absence of dsRNA. The interaction between E3 and PKR is 
different in the presence of higher concentration of dsRNA where E3 forms a nonfunctional 





                                    
 
 
Figure 2.11. Model for the interaction of E3 with PKR and the dsRNA- dependent 
dimerization and activation of PKR.  
The DRBDs of PKR are indicated by the number 1 or 2, for DRBD1 and DRBD2, 
respectively. The hatched box represents the substrate binding domain. The model begins 
with a depiction of PKR in its inactive state, showing the interaction of the regulatory 
domain masking the substrate binding domain (A). This is depicted as occurring via an 
intramolecular reaction but could just as well occur via an intermolecular reaction between 
two PKR molecules giving an inactive dimer. The model goes on to show that pE3 can 
prevent PKR activation by three different mechanisms: in the absence of dsRNA by 
interaction with the substrate binding domain (B) and by the formation of nonfunctional 
heterodimers formed by three different mechanisms (C): in the absence of dsRNA by 
interaction with the substrate binding domain (B); by the formation of nonfunctional 
heterodimers formed by interaction with dsRNA and the DRBDs of PKR (C); and by 
sequestration of dsRNA (D). The active form of PKR is depicted in E. Figure adapted from 





A second model for E3 and PKR interaction was proposed by Romano et al. (Fig. 
2.12). It was suggested that a protein-protein contact occurred between the DRBD domains 
of PKR and E3 with a mutual binding to the same dsRNA that stabilized the complex of 
PKR-E3-dsRNA [13]. Coimmunoprecipitation in yeast extracts, suggested that a majority of 
the PKR molecules in yeast were physically associated with E3 in a manner dependent on the 
dsRNA binding activity of E3 [13]. The yeast two-hybrid and GST pull-down assays 
revealed complex formation between the C-terminal half of E3 and the N-terminal half of 
PKR. These segments contained their DRBDs and the interaction among them also depended 
on dsRNA binding by the E3 protein. Along with coimmunoprecipitation and GST pull-
down assays, it was observed that binding between PKRD243-551 and ED37-86, K167A, 
R168A was rescued by high concentrations of dsRNA, indicating that complex formation is 
critically dependent on the DRBD containing segments of both proteins and dsRNA binding 
by E3 [13]. To summarize the model, an active homodimer of PKR in the presence of 
dsRNA is disrupted by the binding of E3 proteins, thus forming an inactive heterodimer. The 
N-terminal of E3 interacts with the C-terminal of PKR along with interactions between the 
DRBDs of both proteins. Interactions between E3 and PKR requires dsRNA. The inactive 
heterodimer of PKR-E3-dsRNA fails to initiate the immune response during viral infection.  
 The two different models predicted for E3 and PKR interaction emphasized on the 
fact that dsRNA binding ability is required for the E3 to inhibit PKR activity but a recent 
study revealed that for E3 to perform its biological functions, it does not require its 




                                     
 
   
Figure 2.12. Hypothetical model for inhibition of PKR function by E3 through the formation 
of inactive heteromeric complexes.  
PKR is shown schematically with its two DRBMs (R) and the kinase domain depicted as 
rectangles. E3 is depicted with its single DRBM (R) hatched and the N-terminal domain (N) 
shaded. The active form of PKR is depicted as a dimer bound to dsRNA, with dimerization 
mediated by interactions involving the N-terminal region containing the DRBMs, the kinase 
domain, and the region from residues 244 to 296 and by binding to the same dsRNA 
molecule. E3 is shown inhibiting PKR by forming inactive heterocomplexes, disrupting PKR 
homodimers. In addition, the N-terminal domain of E3 is shown interacting with the kinase 
domain of PKR, interfering with some aspect of kinase function. Binding to dsRNA by E3 
greatly contributes to the stability of the PKR-E3 complex. E3 can also inhibit kinase 









3.1. Mutations of VACV E3 protein 
Different single (I110A, K109A, W113A, I122A, F148A, R131A, K167A, 
Y125A, R168A, A174V, A175V, I154A, and F159A) and double mutations (L182A 
L183A, R131A I110A and R131A F159A) of E3 were developed. Forward and reverse 
primers designed for the specific targeted mutation were purchased from Integrated DNA 
Technologies (IDT, IL). PCR was set up with wildtype E3 as a template, mutation 
specific primers, high fidelity KOD DNA polymerase designed for PCR amplification of 
DNA templates (Millipore Sigma, MA) and a total reaction volume of 50 µL. PCR 
conditions were set as follows; initial denaturation at 95°C for 30 seconds, denaturation 
step at 95°C for 30 seconds (16 cycles), annealing for 1 minute at 55°C and finally 
extension at 68°C for 2 minutes with no final extension step. PCR amplified products 
were mixed with DpnI restriction enzyme (New England BioLabs, MA) and incubated 
for an hour at 37°C to digest the parental DNA (nonmutated supercoiled dsDNA). DpnI 
digested products were then transformed into E.coli BL21 (DE3) competent cells (New 
England BioLabs, MA) by electroporation. BL21 (DE3) cells are B strains of E.coli and 
are deficient in Lon protease (cytoplasm) and OmpT protease (outer membrane). These 




 under the control of lacUV5 promoter. In order to induce the expression of T7 RNA 
polymerase to a maximum effect, IPTG (Isopropyl β-D-1-thiogalactopyranoside) is required 
which then expresses the recombinant genes cloned downstream of a T7 promoter [77].  
Electroporated cells were grown at 37°C for an hour and later were plated on 
kanamycin containing LB agar plates. LB agar plates were incubated overnight at 37°C. 
Colonies obtained from the plates were submitted for sequencing which confirmed the 
presence of single point mutations in E3 DNA sequence. The protocol for mutagenesis was 
obtained from Stratagene QuickChangeÒ Site-Directed Mutagenesis Kit. 
 
3.2. Protein expression and purification of VACV E3 mutants 
VACV E3 mutants were cloned into a modified pET28b vector that expressed 
maltose binding protein (MBP) with an N-terminal 6-histidine-tag and a C-terminal tobacco 
etch virus (TEV) protease recognition site (Glu-Asn-Leu-Tyr-Phe-Gln/Gly). A cassette 
containing the coding sequence for E3 mutants under the control of a T7 promoter was 
inserted into the vector (Fig. 3.1). The 6x histidine tag on the fusion protein allows a single 
step purification of protein whereas the MBP tag helps in producing very high yield of fusion 
protein that are soluble and properly folded. The plasmid containing the E3 mutants were 
expressed in E. coli BL21 (DE3) cells with kanamycin. Small-scale expression studies were 
conducted with 50 mL of LB media grown at 37°C to test the different E3 mutants. IPTG at a 
final concentration of 1 mM was added to induce expression of fusion protein when the 
optical density (OD600nm) of the culture reached ~0.8. The temperature for growing the LB 
cultures was reduced to 18°C. After growing the cultures overnight at 18°C, the cells were 






Figure 3.1. Plasmid map for E3 mutants in pMBP28b+ vector.  
A 6x histidine tag on the N-terminal followed by maltose binding protein with E3 mutants on 
the C-terminal separated by TEV protease cleavage site. Both the single mutants and double 
mutants of E3 were cloned in the MBP plasmid.  
 
Cell pellet was homogenized and filtered supernatant was passed through a Ni-NTA 
(Nickel-nitrilotriacetic acid) affinity column (Qiagen, MD). E3 mutants expressed along with 
MBP are highly soluble and because of the 6-histidine tag on the N-terminal, the fusion 
protein bound to the Ni-NTA column. The Ni column was washed multiple times with wash 
buffer and fusion protein that remained bound to the column was eluted using buffer 
containing 250 mM imidazole concentration. The elute from the column was subjected to 
TEV protease digestion which removed the His-MBP tag from the fusion protein and E3 
protein was collected as a flow-through of a second Ni-NTA purification. E3 protein was 
further purified using size exclusion chromatography (SEC) (Superdex 200 Increase 10/300 
GL column, GE Healthcare, MA). Large-scale expression and purification of E3 single and 
double mutants were optimized and conducted in a similar manner as small-scale expression.  
 
3.3. Protein expression and purification of human PKR kinase domain (PKR-KD) 
The full length kinase domain of PKR (amino acids 258-551) was cloned into various 
vectors such as a modified pET28b vector that expressed maltose binding protein (MBP) 




recognition site (ENLYFQG/S) (Fig. 3.2). A modified pET22b vector consisting of 
Glutathione S-transferase (GST) protein along with the TEV protease recognition site was 
also used for cloning the full length PKR-KD (Fig. 3.2). A cassette containing the coding 
sequence for PKR-KD under the control of a T7 promoter was inserted into this vector. The 
GST tag helps in a single step purification of PKR-KD by using a column of immobilized 
glutathione. A shorter PKR-KD (258-541) with the last 10 amino acids from the C-terminal 
deleted was also cloned into MBP vector. A double mutant of full length PKR-KD (H412N, 
C551A) was cloned into both MBP and GST vectors. A single mutant of the shorter PKR-
KD (H412N) was cloned into both MBP and GST vectors. A construct of PKR-KD which 
was used for solving the crystal structure of PKR-KD and eIF2a complex had two mutations 
(H412N and C551A) and a 13 amino acid deletion of a protease sensitive b4 - b5 loop 
(residues 338-350) [45]. This crystallizable construct was also cloned into both the MBP and 
GST vectors. Different constructs were used for expression and purification of PKR-KD in 








(A) A 6x histidine tag on the N-terminal followed by maltose binding protein with PKR-KD 
on the C-terminal separated by TEV protease cleavage site. (B) A glutathione-s-transferase 
tag on the N-terminal and C-terminal PKR-KD separated by TEV protease cleavage site.  
 
The plasmid containing the PKR-KD in GST and MBP vectors were expressed in E. 
coli BL21 (DE3) cells with ampicillin and kanamycin respectively.  Large-scale cultures 
were grown in 1 liter of LB media at 37°C.  IPTG at a final concentration of 1 mM was 
added to induce expression of fusion proteins when the optical density (OD600nm) of the 
culture reached ~0.8. The temperature for growing the LB cultures was reduced to 18°C. 
After growing the cultures overnight at 18°C, the cells were collected by centrifuging at 4713 
x g and kept frozen in -20°C for future use. Cell pellets were homogenized and the 
supernatant was filtered and passed through Ni-NTA affinity column.  
Clones with GST fusion protein were loaded on to a glutathione column. GST fusion 
protein specifically bound to the column. Protein loosely bound to the column were cleaned 
out of the column by a wash buffer. Fusion protein was eluted by adding reduced glutathione 
that displaced the target protein out of the column. The fusion protein was digested by adding 
TEV protease that separated PKR-KD from GST protein.  
In case of the pMBP28b+ vector, a Ni-NTA affinity column was utilized for 
purification. The method of purification followed was similar to the procedure of E3-MBP 
fusion protein purification where 1st Ni purification followed a SEC purification. Fractions 
from SEC purification (Superdex 200 column) containing clean fusion protein were pooled 
and digested with TEV protease to remove MBP from PKR-KD followed by another SEC 




non-specific binding of MBP to PKR-KD and 10% glycerol to prevent precipitation of 
protein at higher concentrations.  
 
3.4. Protein expression and purification of yeast eIF2a 
The N-terminal of yeast eIF2a4_175 was cloned into a pSKB3 vector that expressed a 
N-terminal 6-histidine-tag followed by a tobacco etch virus (TEV) protease recognition site 
(ENLYFQG/S) (Fig. 3.3). A cassette containing the coding sequence for eIF2a under the 
control of a T7 promoter was inserted into the vector.  
              
 
Figure 3.3. Plasmid map for yeast eIF2a in pSKB3 vector.  
A 6x histidine tag on the N-terminal and eIF2a on the C-terminal separated by TEV protease 
cleavage site.  
 
The plasmid containing the eIF2a gene were expressed in E. coli BL21 (DE3) cells 
with kanamycin. Large-scale cultures were grown in 1 liter of LB media at 37°C. IPTG at a 
final concentration of 1 mM was added to induce expression of fusion proteins when the 
optical density (OD600nm) of the culture reached ~0.8. The temperature for growing the LB 
cultures was reduced to 18°C. After growing the cultures overnight at 18°C, the cells were 
collected by centrifuging at 4713 x g and kept frozen in -20°C for future use. Cell pellets 
were homogenized and the supernatant was filtered and passed through a Ni-NTA affinity 




N-terminal was eluted out of the column using a buffer consisting of 250 mM imidazole. The 
eluted protein was passed through a SEC Superdex 200 column as a final step of purification. 
The fusion protein was used for in vitro kinase assays without removal of the 6-histidine tag.  
 
3.5. Protein characterization 
The final purified proteins of E3 and PKR-KD were characterized by dynamic light 
scattering (DLS) (Zetasizer µV, Malvern Panalytical, UK) and size exclusion 
chromatography. DLS was used to detect aggregation state of the purified E3 mutants and the 
monomeric/dimeric state of PKR-KD. The data from DLS also provided information 
regarding the oligomeric state of SEC fractions along with mono or polydisperse nature of 
the E3 proteins. Molecular weight of protein was also estimated by SEC using a standard 
provided by the manufacturer (catalog # 1511901, BIO-RAD, CA).  
 
3.6. Thermal shift assay of E3 proteins using Real-Time PCR (RT-PCR) 
Thermal shift assays involve incubation of natively folded proteins with fluorescent 
dye in a 96 well PCR plate. The thermal denaturation of a protein in many conditions can be 
detected simultaneously by increasing the temperature systematically while monitoring the 
fluorescence emission. The increase in melting temperatures in different conditions give rise 
to a ‘thermal shift’ that quantifies the stabilization of the protein under different buffer or 
additive conditions [78].  
 The stability of E3 protein with different additives was tested by conducting real-
time PCR. SYPRO orange (catalog # S5692, Millipore Sigma, MA) was used as a 




470 nm, emission at 570 nm and undergoes a significant increase in quantum yield when it 
binds to hydrophobic regions in denatured proteins yet it is compatible with filter sets found 
in real-time PCR equipment for detecting protein thermal denaturation assays [79]. An 
additive screen with 96 different conditions (catalog # HR2-428, Hampton Research) was 
used for the thermal shift assay. Total reaction volume of 50 µL had buffer (20mM TrisHCl, 
150mM NaCl, pH 7.5), E3 protein, different additives and SYPRO orange dye. A 96 well 
PCR plate was used for setting up the reactions. The stability of E3 protein was scanned over 
the temperatures of 25°C to 95°C with an increment of 1°C. The raw fluorescence emission 
data from real-time PCR machine was converted to a first derivative as a function of 
temperature and plotted against the different temperatures used.  
 
3.7. In vitro binding assay between PKR-KD and E3 proteins 
E3 and PKR-KD proteins were purified separately and added in a molar ratio of 2:1 
or 1:1 along with 1 mg/mL of AMP (Adenosine monophosphate). AMP was added to 
activate PKR protein. The protein mixture was incubated at 4°C for an hour and was applied 
to Superdex 200 SEC column in a buffer containing either 500 mM or 300 mM NaCl. The 
chromatogram from the SEC purification was compared to the individual purification 
chromatograms of E3 and PKR-KD to determine the formation of a complex between these 






3.8. Pull down assay for E3 and PKR-KD protein interaction 
E3 fusion protein (HisMBPE3[R131A]) with 6x-His-MBP tag was used for pull 
down assays with PKR-KD. E3 fusion protein and PKR-KD were added in a molar ratio of 
2:1 and incubated at 4°C for an hour. This protein mixture was applied to a 200µL Ni-NTA 
column. Flow-through from the column was collected. Wash buffer containing 5 mM 
imidazole was passed through the column twice and the washes were collected. Protein 
binding to the column was eluted by a buffer containing 250 mM imidazole. The collected 
fractions from the Ni column purification were added with SDS loading buffer, boiled and 
electrophoresed on 15% SDS-PAGE gels. The SDS gels were transferred to polyvinylidene 
difluoride (PVDF) membrane (Immobilon -P, Millipore Sigma, MA) and blotted with an 
antibody that recognizes PKR residues 435 to 449 (catalog # PA1-990, Invitrogen, CA). A 
chemiluminescent substrate (catalog # 34077, Thermo scientific, IL) was added to the 
membranes and visualized under chemiluminescence (FluorChem E, Proteinsimple, CA). A 
control reaction was set up with a fusion his-MBP tagged STF protein and PKR-KD. STF is 
an unrelated plant protein that has no known binding with PKR. Similar procedure was 
followed as before and chemiluminescence was visualized and documented. The entire 
procedure was also conducted for PKR-KD only to eliminate the possibility of non-specific 
binding of PKR-KD to Ni column. The western blot membranes were quantified using Image 
J software. 
 
3.9. In-vitro kinase assay between E3 and PKR-KD 
Purified PKR-KD (monomer) or GST-PKR-KD (dimer) were diluted in a kinase 




proteins were then incubated with equimolar quantities of His-tagged eIF2a4_175 recombinant 
protein and varying amounts of E3[R131A] mutant in the presence 500 µM ATP. The total 
reaction volume was 50 µL with the final concentrations of PKR-KD, GST-PKR-KD and 
His-eIF2a4_175 as 1 µM in the reaction mixture. The final E3 concentrations were set up as 0, 
3.2, 6.4, 12.9, 25.7 and 51.4 µM. After 25 minutes of incubation at 4°C, samples were mixed 
with SDS loading buffer, boiled and electrophoresed on 15% SDS-PAGE gels, transferred 
onto a polyvinylidene difluoride membrane (PVDF) (Immobilon -P, Millipore Sigma, MA) 
and blotted with anti-phospho-ser51 eIF2a antibody (catalog # PA5-37800, Invitrogen, CA) 
or anti-his antibody (catalog # MA1-80218, Invitrogen, CA). A chemiluminescent substrate 
(catalog # 34077, Thermo scientific, IL) was added to the membranes and visualized under 
chemiluminescence (FluorChem E, Proteinsimple, CA). The western blot membranes were 
quantified using Image J software.  
 
3.10.  In-vitro autophosphorylation assay 
Purified PKR-KD (monomer) or GST-PKR-KD (dimer) were diluted in a kinase 
reaction buffer made up of 17 mM MgCl2, 60 mM HEPES [pH 7.0], 0.2 mM DTT. The PKR 
proteins were then incubated with equimolar quantities of His-tagged eIF2a4_175 recombinant 
protein and varying amounts of E3[R131A] mutant in the presence 100 µM cold ATP 
supplemented with 5 µCi of g32P ATP. The total reaction volume was 50 µL with the final 
concentrations of PKR-KD, GST-PKR-KD and His-eIF2a4_175 as 1 µM in the reaction 
mixture. The final E3 concentrations were set up as 0, 3.2, 6.4, 12.9, 25.7 and 51.4 µM. After 
25 minutes of incubation, samples were mixed with SDS loading buffer, boiled and 




A phosphorimager (Typhoon TRIO, GE Healthcare) was used for visualizing the 
radioactive gels that were exposed to a phosphor imager screen (catalog # 00314394 8x10, 
Amersham Biosciences) for a week. The phosphor imager screens were exposed to visible 
light (Image Eraser, Amersham Biosciences) to erase any latent image from previous 
radiation exposure. These phosphor imager screens are used for recording and quantifying 
radioactive gels [80]. The screens are made up of crystals of BaFBr:Eu+2 and when exposed 
to ionizing radiation such as a, b or g, oxidation of Eu+2 to Eu+3 occur which form a latent 
image on the screen. The luminescence produced during Eu+3 reverting back to Eu+2 gets 
collected during scanning at 633 nm and released as the latent image from the screen [81]. 
The image was viewed through the phosphorimager and quantified using ImageJ software. 
 
3.11.  Crystal screen set-up of E3 proteins 
The dimeric E3[R131AI110A] protein in 20 mM TrisHCl, pH 7.5 and 500 mM NaCl 
was concentrated to approximately 3mg/mL (0.125 µM) and was used for setting up crystal 
trays using three different crystal screen kits. The kits used were PEG/ION Screen (HR2-098, 
Hampton Research), Index (HR2-144, Hampton Research) and The BCS Screen (MD1-104, 
Molecular Dimensions). Each reservoir in the crystal tray was filled with 50 µL of screen kit 
solution and each crystal drop had 0.5 µL of protein with 0.5 µL of solution from the 
reservoir. A sitting drop vapor diffusion technique was used for setting up crystal trays in this 
case and the trays were stored at room temperature. A total of 288 conditions were tested 





3.12.  Scanning of crystal trays 
The crystal trays with the dimeric E3[R131AI110A] protein were scanned for protein 
crystal formation. The scanning of trays were conducted using a compound microscope and 
the schedule for observation was set as every day for a week after the day of setting the tray, 
once every two weeks and once a month thereafter. The trays were scanned for protein 
crystals under the microscope. Each droplet was examined carefully and the observations 






PURIFICATION OF VACV E3 MUTANTS 
 
4.1. Introduction  
A major gap in the knowledge of E3 protein is the understanding of its structure. 
E3 plays a major role in antagonizing the host immune response. With a broad host 
range, it makes a perfect candidate for drug development and viral vectors, for treating 
other diseases. Understanding the structure of E3 protein would be a path forward in that 
direction. Our goal in this study was to determine the x-ray structure of the full-length E3 
protein to provide a more complete structural framework. It would provide us with a 
better understanding of the functional aspects of E3.  
A distinctive property of the full-length E3 protein is its inherent ability to 
oligomerize in solution. This helps the E3 protein to enter into the nuclear compartment 
of the host cell with, either directly altering the physical state of the protein or indirectly 
preventing the export of cytoplasmic E3 proteins into the nucleus [15]. An early study on 
physical and chemical characteristics of E3 reported that the extent of oligomerization of 
E3 at equilibrium is governed by solution conditions, particularly ionic strength. 
Sedimentation analysis suggested that the native form of E3 at 1 M NaCl is likely to be a 
dimer. This was supported by the formation of crosslinked E3 dimers upon incubation 




E3 behaved, on average, as a trimer at 0.5 M NaCl [16]. The oligomerization state is 
dependent on protein concentration, thus the experimental data from the above mentioned 
study, that used a lower concentration of 0.25 mg/mL may not be reproducible for a higher 
concentration of E3 protein. 
Crystallization studies require a protein to be highly soluble, pure, homogenous and 
monodispersed (of a single multimerization state). Wild type E3 proteins is highly soluble 
but purifies as an aggregate which is a big problem for protein crystallization. The idea of 
using protein engineering to alleviate aggregation towards structural studies, is motivated 
from a recent success on a non-related difficult protein project conducted by a group at 
Baylor College of Medicine, Texas [17].  NS1 protein from H5N1 influenza virus suppresses 
antiviral interferon (IFN) induction in the host cells but how the protein antagonizes the IFN 
response was unknown [18]. NS1 protein remains in an aggregated form in the cytoplasm of 
the host cell similar to E3 protein. Aiming to solve the atomic structure of NS1 by 
crystallography, the group performed a series of single point mutations where they 
determined two single mutations that completely removed aggregation. The approach 
allowed them to crystallize the NS1 protein and perform structural analysis of the crystal 
[17]. Similarly, it was predicted that single/double point mutations of E3 proteins might 
mitigate the problem of aggregation and thus help in the structural studies of this protein 
through x-ray crystallography. Alanine scanning or valine substitution (in the case of alanine 
residues) mutagenesis on the DRBD (Double stranded RNA inding Domain) of E3 protein 





4.2. Results and Discussion  
 
4.2.1. E3 mutants purify as an aggregate except for two mutants R131A and F148A 
The inherent nature of E3 protein is to remain in an aggregated form in solution. In 
this study, we predicted that single point mutations in the DRBD would abrogate E3 
aggregation. In order to test this prediction, alanine scanning or valine substitution (in the 
case of alanine residues) mutagenesis on the DRBD of E3 protein was performed. These 
mutants were chosen based on their dsRNA binding ability and host range function in a 
different study [14]. The different E3 mutants were individually expressed in bacterial cells 
and purified using various purification methods. Molecular weight and aggregation level of 
E3 protein purified were measured and characterized by size exclusion chromatography 
(Table 4.1). It was observed that most of the mutants purified as aggregates (a high molecular 
weight protein eluting in the void volume of the size exclusion chromatography column) 
similar to wildtype E3 protein. The E3 mutants R131A and F148A purified as lower 
molecular weight oligomers with some aggregates. These amino acid residues must be 

















Table 4.1. Purification of E3 mutants and their ability for dsRNA binding and host range 
function. (*data obtained from reference [14]).       






The SEC chromatograms of the final purification step of E3[R131A] and other E3 
mutants were compared (Fig. 4.1). As all of the other mutants except for R131A and F148A, 
had a similar chromatogram profile, just one of the chromatogram was compared with 
R131A as a representative. The SDS-PAGE gels on the SEC fractions indicate the presence 
of E3 and maltose binding protein (MBP) protein based on their molecular weights (Fig. 4.1). 
A non-specific binding of MBP with E3 led to the presence of MBP in the final purification 
step. Optimization of the purification process was conducted to obtain a clean and 
homogeneous protein which could be used for x-ray crystallography.  
                                         





                                                  
Figure 4.1. Comparison of size exclusion chromatograms of E3[R131A] and E3[I105A] 
mutants.  
 
(A) SEC profiles of the E3[R131A] which purified as a lower oligomeric E3 proteins (red 
chromatogram) as compared to E3[I105A] that purified as an aggregate and eluted mostly 
in void volume of size exclusion chromatography purification (black chromatogram). Most of 
the E3 mutants except for E3[R131A] and E3[F148A] purified as aggregates and only one of 
the chromatograms was used for comparison. (B) Corresponding SDS-PAGE gels for the 
fractions collected from the chromatograms mentioned in A. The 1st SDS gel on top 
represents the E3 mutants that eluted as aggregates whereas the 2nd gel on bottom 
represents the fractions from E3[R131A] SEC purification. The 1st lane of the gels is the 
protein ladder, 2nd lane is the sample that was loaded on the SEC, lanes corresponding to 
E3 aggregates are the fractions from the void volume, lanes showing E3 oligomers for 
E3[R131A] gel represent the peak for E3 oligomeric protein and finally the fractions with 
MBP are the last few lanes in the gel.  
 
4.2.2.  Optimization of purification steps for E3[R131A] mutant 
Based on the small-scale expression studies, E3[R131A] mutant was used for 
optimizing the purification process for large-scale production of the protein (Fig. 4.2). Large-
scale production of E3[R131A] was conducted to purify a lower molecular weight oligomer, 
which could be used for crystallization studies. Multiple optimization steps were performed 
during the purification process.  
Optimization was performed to avoid the non-specific binding of MBP to E3 protein 
during purification. Since MBP is a maltose binding protein, the natural target was to add 
maltose to the purification buffers. Different concentrations of maltose were tested ranging 
from 10 mM to 100 mM in buffers for E3 purification. An optimum concentration was 




of the buffers used for E3 purification steps. Flow-through from affinity purification after 
digestion of fusion protein should contain only E3 protein and MBP which still has the 6x 
His-tag should stay bound to the nickel column. A big difference in quality of the flow 
through was observed with and without 40 mM maltose in purification buffers (Fig. 4.3).  
                      
Figure 4.2. SDS-PAGE gel for affinity purification of the fusion protein.  
1st lane of the SDS-PAGE gel is the protein marker denoted in KDa, 2nd and 3rd lane 
corresponds to before and after induction with IPTG samples respectively of cell culture, 4th 
represents the filtered supernatant that was passed through the nickel column,5th is the flow-
through, 6th and 7th are the washes with buffer containing 1M NaCl, rest of the lanes are 
fractions of fusion protein eluted by using buffer containing 250mM imidazole.  
 
The binding capacity of a nickel column is 20 – 40 µmoles Ni2+/ml resin (Qiagen). A 
loss of binding capacity of the nickel resin was observed with multiple usage for purification. 
It was observed, while purifying the E3 mutants, that the same column used for more than 
two times led to MBP eluting with the target protein due to the loss of binding capacity. 
Regenerating the Ni-NTA column did not improve the binding capacity. Using a fresh Ni-







Figure 4.3. SDS-PAGE gels for affinity purification of E3 protein after digestion of MBP tag 
with and without 40mM maltose in purification buffers.  
(A) SDS gel for fractions from an affinity purification after digestion of the MBP tag from the 
fusion protein (MBP-E3 protein) with no maltose in the purification buffers. The 1st lane 
corresponds to fusion protein before digestion (70 KDa), 2nd lane is the fusion protein after 
digestion with 2 different proteins (MBP = 44 KDa and E3 = 25 KDa), 3rd is the flow 
through which should have only E3 but has both MBP and E3, 4th and 5th lanes are washes 
with buffer containing 5mM imidazole and 6th and 7th lanes are fractions from elutions with 
250mM imidazole. (B) SDS gel for fractions from an affinity purification after digestion of 
the MBP tag from the fusion protein (MBP-E3 protein) with 40mM maltose in the 
purification buffers. The lanes represents the fractions exactly like the gel shown in A. The 
flow through have a cleaner E3 protein as compared to the flow through without maltose as 
shown in A. 
 
As a final step of purification, the flow-through and washes from the affinity 
purification of digested fusion protein consisting of E3 protein were subjected to SEC using a 
Superdex 200 column. The chromatogram of the SEC showed a broad peak which 
encompassed some aggregates and oligomers calculated to range from eighteen E3 molecules 
to dimers/trimers (Fig 4.4) based on the elution volumes relative to standards and DLS 
(Table 4.2).  
 




            
              
 
Figure 4.4. SEC chromatogram and its corresponding SDS-PAGE gel for the fractions.  
(A) Chromatogram of the SEC for the last step of purification of E3 protein with buffer 
containing 500mM NaCl and 40mM maltose. The broad peak contained different oligomeric 
state of E3 along with a small amount of aggregates. (B) SDS-PAGE gel of the 
chromatogram shown in A with fractions from the SEC. E3 protein was observed at the 







Table 4.2. Estimated molecular weight of different fractions of SEC purification of 
E3[R131A] protein.  
Molecular weight was determined by SEC and DLS. 
              
   
 
The fractions with different oligomeric states of the E3[R131A] mutant were 
homogenous. It was observed that each of these fractions if taken individually and 
concentrated to protein concentration required for crystallographic studies, caused 
aggregation. Another condition where these fractions reverted back from dimers/trimers to 
aggregate was storage of the fractions in -80°C (long-term storage). It has been observed that 
the expression and purification of recombinant proteins could be considerably improved with 
the addition of stabilizing solutions or additives that reduce the tendency of proteins to unfold 
or aggregate during purification and storage in vitro [78]. Also, increasing stability could 




In order to improve the stability of the E3[R131A] fractions, thermal shift assays 
were conducted using real-time PCR to scan different additives and solutions (Table 4.3). A 
selection of 96 different additives were tested, and the raw data from real-time PCR was 
converted into a 1st derivative of the fluorescence emission as a function of temperature. It 
was found that addition of salts such as 100 mM ammonium sulfate, 100 mM sodium citrate 
tribasic dihydrate and 100 mM sodium malonate pH 7.0, increased the melting temperature 
(Tm ) of E3[R131A] protein (Fig. 4.5). In addition to the three salts, few other salts such as 
100 mM potassium chloride, 200 mM sodium thiocyanate, 100 mM potassium sodium 
tartrate tetrahydrate and 100 mM cesium chloride, also had an insignificant effect on the Tm 
of E3. An increased melting temperature correlates to increased stability of a protein. With 
addition of the above mentioned salts to E3[R131A] fractions leads to an increased stability 
of the protein. Thus, buffers containing these salts could be used to purify E3 to obtain 
homogenous and stable protein.  
The other additives or solutions either had no or negative effect on the Tm (individual 
graphs are shown in Appendix section). Fluorescence emission was not observed in case of 
detergents, reducing agents and co-factors suggesting, denaturation or precipitation of the 
protein in presence of these additives. These additives should not be used for E3 purification 







Figure 4.5. Thermal shift analysis of protein stability in different salt solutions.  
The x-axis represents the increasing temperature during thermal shift assays whereas the y-
axis corresponds to the first derivative of the fluorescence emission as a function of 
temperature (d[fluorescence]/dT). The melting temperature (Tm) is represented as the 
highest part of the curve. The solid green curve represents the Tm of E3[R131A] protein 
without any additives. The additives that had a prominent increased effect on the protein 
were 100 mM sodium citrate tribasic dihydrate, 100 mM sodium malonate pH 7, 100 mM 











Table 4.3. Different additives (Additive screen, HR2-428, Hampton Research) used for 









Table 4.3. (Continued) Different additives (Additive screen, HR2-428, Hampton Research) 







Our goal was to purify E3 protein with homogenous fractions that does not form 
aggregates at higher protein concentration. To achieve this goal, purification of E3[R131A], 
was performed with buffers containing salts that increased the Tm of the protein such as 100 
mM ammonium sulfate [(NH4)2SO4], 100 mM sodium citrate tribasic dihydrate (Na3C6H5O7) 
or 100 mM sodium malonate (C3H2O4Na2) pH 7, instead of 500 mM NaCl. After 
purification, the molecular weight of E3 protein (fraction # 19) of each SEC purification 
using different buffers was determined by DLS and compared with the fraction # 19 of SEC 
purification using 500 mM NaCl (Table 4.4).   
 
Table 4.4. Estimated molecular weight of fraction # 19 of SEC purification of E3[R131A] 
protein using different buffers.  
 
 
The DLS data demonstrated that E3 purified in buffers other than 500 mM NaCl tend 
to aggregate and remain polydispersed. These salt additives increased the melting 
temperature and stability of E3 but at the same time increased the heterogeneity of the 
protein. Buffer containing 100 mM ammonium sulfate had the maximum aggregation. 
Buffers with 100 mM sodium citrate tribasic dihydrate and 100 mM sodium malonate 
although were comparable to buffer with 500 mM NaCl, an increase in heterogeneity of the 




polydisperse or monodisperse (homogeneous) state of the protein in the above mentioned 
table. Based on these results, subsequent purification and optimization of E3[R131A] was 
conducted with 500 mM NaCl without any additives added to the buffer.  
To test another strategy for obtaining E3[R131A] homogeneous protein, a single 
fraction (fraction # 24) from SEC purification of E3[R131A] was processed through SEC 
column again for resizing (Fig. 4.6).  
 
 
Figure 4.6. Resizing of E3[R131A] fraction  
(A) Chromatogram of the SEC for the last step of purification of E3 protein with buffer 
containing 500mM NaCl and 40mM maltose. The broad peak contained different oligomeric 
state of E3 along with a small amount of aggregates. SDS-PAGE gel under the 
chromatogram represents the different fractions from the broad E3 purification peak. (B) 
Chromatogram of SEC conducted on fraction # 24 of the broad peak in SEC shown in A in a 
buffer containing 500mM NaCl. The chromatogram represents a sharp peak of E3 dimers 
and some E3 oligomers. The corresponding SDS-PAGE gel is shown under the 





The estimated molecular weight of fraction # 24 of the SEC purification of 
E3[R131A] mutant was measured using SEC standards and DLS. It was found to be around 
120 KDa which corresponds to approximately five E3 molecules. Results from the resizing 
of fraction # 24 show that E3 eluted as a dimer (MW confirmed with SEC standards) with a 
small amount of E3 oligomers. Due to the sharp peak in the chromatogram, it was assumed 
that the E3 dimers are in a homogeneous state. These results suggested progress towards the 
effort for crystallization of E3 proteins. Unfortunately, when these resized fractions were 
concentrated to near saturation, aggregation (confirmed by DLS) was observed.  
Although these samples were not used for setting up crystal screening of E3 proteins, 
a procedure was developed for protein purification of E3 mutants that could lead to low 
molecular weight homogeneous oligomeric protein without aggregation. With further 
optimization, these E3 dimers and trimers could effectively be used for crystallization 
studies.  
 
4.2.3.  Purification of E3[R131AI110A] mutant 
Purification of the double mutant E3[R131AI110A] was conducted similarly as 
performed for single mutant E3[R131A], in an effort to obtain stable and homogenous E3 
protein. SEC fraction (fraction # 27) was passed through Superdex 200 column for resizing 








Figure 4.7. Resizing of E3[R131AI110A] fraction  
(A) Chromatogram of the SEC for the last step of purification of E3 protein with buffer 
containing 500mM NaCl and 40mM maltose. The multiple peaks contained different 
oligomeric state of E3 along with aggregates. SDS-PAGE gel under the chromatogram 
represents the different fractions from multiple E3 purification peaks. (B) Chromatogram of 
SEC conducted on fraction # 27 of the last peak in SEC shown in A in a buffer containing 
500mM NaCl. The chromatogram represents a sharp peak of E3 dimers and some E3 
oligomers. The corresponding SDS-PAGE gel is shown under the chromatogram and E3 
protein was observed at the expected molecular weight of ~25 KDa.  
 
Results showed that the fraction # 27 of E3[R131AI110A] had a molecular weight of 
44 KDa which corresponds to approximately two E3 molecules. The resizing of fraction # 27 
of E3[R131AI110A] led to the elution of E3 as a dimer (MW confirmed with SEC standards) 
with a small amount of E3 oligomers. Due to the sharp peak in the chromatogram, it was 
assumed that the E3 dimers are in a homogeneous state. When these resized fractions were 
concentrated to ~3mg/mL, the protein remained as a dimer (confirmed by DLS) as compared 




from the SDS-PAGE gel of resizing fractions was conducted to confirm the identity of the 
protein and was found to be E3 from VACV (Appendix).  
These results are an important progress towards the effort for crystallization of E3 
proteins. The concentrated dimeric protein samples were proceeded for crystallization set up 
with various crystal screening kit available commercially.  
  
4.3. Conclusion 
Various surface mutations were conducted in an effort to reduce the inherent nature 
of E3 to aggregate. Two mutants (R131A and F148A) were successfully expressed and 
purified to produce lower oligomeric protein but did not completely abrogate the problem of 
aggregation. Optimization of purification led to a procedure that could potentially produce 
homogeneous dimeric proteins. An E3 double mutant (E3[R131AI110A]) displayed the best 
results when purified and concentrated to a desired concentration for crystallization. Unlike 
E3 single mutants, the double mutant had better stability and was a likely candidate for 
crystallization screening process. Crystal screening was conducted with the double mutant 





PHYSICAL INTERACTION OF VACV E3 AND HUMAN PKR-KD 
 
5.1. Introduction 
The human PKR protein is an important dsRNA-dependent serine/threonine 
protein kinase, which activates the innate immune response during viral infections. Due 
to its vital function, viruses implement numerous strategies to eliminate PKR’s immune 
response activity. One of these strategies include VACV E3 proteins that are produced 
early in the viral replication cycle to prevent activation of dsRNA-activated PKR.  
Models proposed in previous studies suggested that E3 inhibited PKR activity in a 
yeast system and this inhibition correlated with the physical interaction between the two 
proteins [13, 75].  A more recent study have shown physical interactions between these 
two proteins in vivo in HeLa cells and in vitro using GST pull down assay and correlated 
the interaction with the dsRNA binding capacity of E3 proteins [14]. There has to be a 
physical interaction between E3 and PKR to prevent PKR from inducing the immune 
response. Different predicted models have hypothesized that E3 forms an inactive 
heterodimer with PKR in the presence of dsRNA, which eventually leads to inhibition of 
PKR activity [13, 75].  
PKR activation starts with dimerization of the protein, which occurs via the N-




 dsRNA binding to the N-terminal leads to dimerization and thus activation of PKR but a 
second patch of residues (amino acids 244-296) in the kinase domain is also known to be 
essential for dimerization [67]. A study indicated that multiple deletions within the patch of 
amino acids 244 and 296 in the kinase domain interfered with the dimerization of PKR and 
thus its activation [85]. The kinase domain of PKR is important during activation as the 
orientation of two kinase domains in a parallel, back-to-back manner leads to 
autophosphorylation which is the next step of PKR activation. All these facts emphasize the 
importance and self-sufficiency of kinase domain in PKR activation. 
In this study, we hypothesized that E3 physically interacts with PKR kinase domain 
and the interaction does not depend on the dsRNA binding ability of either E3 or PKR. To 
test this hypothesis, we conducted in vitro binding and pull down assays with E3 and PKR-
KD to determine the physical interaction between the two proteins and also the stoichiometry 
of this interaction.  
 
5.2. Results and Discussion  
 
5.2.1.  PKR-KD purifies in a monomer-dimer equilibrium state 
Purification of the individual protein was required to test for the physical interactions 
between E3 and PKR-KD. It was observed that expression of the full kinase domain 
(residues 258-551) in E.coli cells resulted in cell toxicity. Previous studies had shown that 
amino acids, histidine 412 and cysteine 551 on kinase domain of PKR, caused toxicity of 
PKR-KD expression in bacterial cells. Mutations H412N and C551A reduced the amount of 




instability, respectively [45, 86]. We used a shorter construct of kinase domain (residues 258-
541) in this study, which reduced cell toxicity but had a low protein yield.  
To obtain PKR-KD protein, MBP or GST tagged PKR-KD constructs with the double 
mutations were expressed and purified. The MBP-tagged protein purified as dimer and 
monomer (Fig 5.1) whereas GST-tagged protein purified mainly as dimer. A construct with 
double mutation and a 13 amino acid deletion (residues 338-350, b4 - b5 loop) cloned into 
GST vector was used also used for expression and purification. Purification of this construct 
led to PKR-KD dimer protein (Fig 5.1). The different constructs and the corresponding 




Figure 5.1. Purification of PKR-KD protein  
(A) Chromatogram of the SEC for the last step of purification of PKR-KD258_551[H412N/_ 
C551A] (MBP vector) protein with buffer containing 500 mM NaCl and 40 mM maltose. 
Protein purified in an equilibrium of monomer and dimer along with aggregates eluted in the 
void volume of SEC column. SDS-PAGE gel (under the chromatogram) of the fractions 
collected in SEC show the presence of PKR-KD protein at ~37 KDa. (B) Chromatogram of 




vector) protein with buffer containing 150mM NaCl and 5mM DTT. Protein purified mainly 
as a dimer with no aggregates eluting in void volume of SEC column. SDS-PAGE gel (under 
the chromatogram) of the fractions collected in SEC show the presence of PKR-KD protein 
at ~37 KDa. 
 
SDS-PAGE gels were loaded with the SEC fractions to measure the molecular weight 
of monomeric PKR-KD, which is approximately 33 KDa but as observed on the SDS-PAGE 
gels shown in Figure 5.1, the protein electrophorized at ~37 KDa. The reason for the higher 
molecular weight in SDS-PAGE gels could be the presence of phosphorylated PKR-KD. The 
phosphorylated protein moves slower than unphosphorylated protein in a gel.  
 
Table 5.1. Different constructs of PKR-KD with the vectors used and the purified state of 




The PKR-KD in pMBP28b+ vectors purified in a weak equilibrium of dimers and 
monomers which upon long term storage in -80°C or short term storage in 4°C/-20°C led to 





5.2.2.  Pull down assay displays the interaction of E3 and PKR-KD 
Pull down assays were performed to determine the physical interactions between E3 
and PKR-KD in the absence of dsRNA binding ability for both proteins. These assays were 
performed for both monomeric and dimeric PKR-KD separately to determine the difference 
in interaction with E3. The protein mix of His-MBP-E3 and monomeric PKR-KD were 
passed through 200 µL of Ni-NTA column. Fractions from flow-through, washes and elution 
were electrophoresed in SDS-PAGE gels. Protein bands corresponding to the molecular 
weights of His-MBP-E3 and PKR-KD were observed on the SDS-PAGE gels (Fig. 5.2, Panel 
A). This suggested that monomeric PKR-KD eluted along with His-MBP-E3 protein due to a 
physical interaction between these proteins.  
As a negative control, only monomeric PKR-KD protein was passed through a Ni-
NTA column. SDS-PAGE gels on these fractions showed the presence of PKR-KD in flow-
through and washes but not in the elution (Fig. 5.2, Panel B). PKR-KD does not bind non-




                                
 
Figure 5.2. Pull down assay of monomeric PKR-KD with His-MBP-E3 protein  
(A) SDS-PAGE gel of the pull down assay of PKR-KD and His-MBP-E3[R131A]. The 1st 
lane on the SDS-PAGE gel corresponds to His-MBP-E3 protein followed by PKR-KD. FT1 
represents the flow-through collected after His-MBP-E3 protein was added to the column. 
The column was washed with buffer containing 5mM imidazole which is represented as W1 
and W2. FT2 represents the flow-through collected after monomeric PKR-KD protein was 
added to the column. The column was washed again with buffer containing 5mM imidazole 
which is represented as W1 and W2. Proteins were eluted off the column by using a buffer 
with 250mM imidazole and shown on the figure as E1. (B) SDS-PAGE gel of pull down assay 
of only PKR-KD. The fractions on the gel are similar to the fractions described in panel A.  
 
Dimeric form is an activated state of PKR-KD, which is formed against viral 
infections to trigger the immune response. Pull down assay was conducted to test whether 
dimeric PKR-KD physically interacted with E3. SDS-PAGE gel on the pull down assay 
fractions showed the absence of PKR-KD in the elution fractions along with His-MBP-E3 




through and in washes. These results suggested that dimeric PKR-KD and E3 protein do not 
interact with each other.  
A negative control with only dimeric PKR-KD was conducted. The SDS-PAGE gel 
showed an absence of dimeric PKR-KD in the elution fraction suggesting a lack of non-
specific binding of dimeric PKR-KD to the Ni-NTA column (Fig. 5.3, Panel B). 
 
                
 
Figure 5.3. Pull down assay of dimeric PKR-KD with His-MBP-E3 protein  
(A) SDS-PAGE gel of the pull down assay of PKR-KD and His-MBP-E3[R131A]. The 
mixture of monomeric PKR-KD and His-MBP-E3[R131A] protein was passed through a Ni-
NTA column. The 1st lane on the SDS-PAGE gel corresponds to His-MBP-E3 protein 
followed by PKR-KD. The protein mix was loaded on the 3rd lane. FT represents the flow-
through collected after the protein mix was added to the column. The column was washed 
with buffer containing 5mM imidazole which is represented as W1 and W2. Proteins were 
eluted off the column by using a buffer with 250mM imidazole and shown on the figure as E1, 
E2 and E3. (B) SDS-PAGE gel of pull down assay of only PKR-KD. The fractions on the gel 





 Western blot analysis of the pull down assays were conducted to confirm the results 
observed in the SDS-PAGE gels shown in figure 5.2 and 5.3. Pull down assays were 
conducted for both monomeric (Fig. 5.4, Panel A) and dimeric PKR-KD (Fig. 5.5, Panel A) 
with His-MBP-E3 proteins individually. The SDS-PAGE gels were transferred to a PVDF 
membrane and blotted against an anti-PKR-KD antibody. It was observed that monomeric 
PKR-KD eluted along with His-MBP-E3 whereas dimeric PKR-KD did not elute with His-
MBP-E3. Unbound PKR-KD protein was observed in the flow-through fractions and also in 
washes. These results suggested that there is a physical interaction between E3 and 
monomeric PKR-KD but absent in case of dimeric PKR-KD. This interactions between 
E3[R131A] and monomeric PKR-KD does not require the dsRNA binding ability of either 




Figure 5.4. Western blots of pull down assay of monomeric PKR-KD with His-MBP-
E3[R131A]  
(A) Pull down assay of PKR-KD and HisMBPE3[R131A] and blotted against antibody that 
recognizes PKR residues 435 to 449). The mixture of monomeric PKR-KD and 
HisMBPE3[R131A] protein was passed through a Ni-NTA column. The 1st fraction on the 
western blot corresponds to the protein mix or supernatant (S) followed by the flow-through 




W1 and W2. Proteins were eluted off the column by using a buffer with 250mM imidazole 
and shown on the figure as E1, E2 and E3. (B) Pull down assay of PKR-KD and His-MBP-
STF. The fractions on the western blot were similar to the fractions described in panel A. (C) 
Pull down assay for PKR-KD only. PKR-KD protein was passed through the column (S) and 
the flow-through (FT) fraction was collected, washes W1, W2  had PKR-KD protein but 
elution fractions E1, E2 and E3 did not have any PKR-KD protein.  
 
A negative control experiment was conducted with His-MBP-STF and 
monomeric/dimeric PKR-KD. STF (Stenofolia)) is a DNA binding plant protein and has no 
known association with human PKR protein. Monomeric/dimeric PKR-KD and His-MBP-
STF were added in a molar ratio of 1:2, incubated for an hour at 4°C and passed through 200 
µL of Ni-NTA column. Most of the PKR-KD proteins were observed in flow-through and 
wash fractions but nothing eluted along with His-MBP-STF, indicating the non-interaction of 
STF and PKR-KD (Fig. 5.4, Panel B and Fig. 5.5, Panel B). A second negative control 
experiment was also conducted with only monomeric/dimeric PKR-KD. Absence of PKR-
KD in the elution fractions, as observed in the western blots, suggested lack of non-specific 
binding of PKR-KD to the Ni-NTA column (Fig. 5.4, Panel C and Fig. 5.5, Panel C).  
 
 
                    




(A) Pull down assay of PKR-KD and HisMBPE3[R131A] and blotted against antibody that 
recognizes PKR residues 435 to 449). The mixture of dimeric PKR-KD and 
HisMBPE3[R131A] protein was passed through a Ni-NTA column. The 1st fraction on the 
western blot corresponds to the protein mix or supernatant (S) followed by the flow-through 
(FT). The column was washed with buffer containing 5mM imidazole which is represented as 
W1 and W2. Proteins were eluted off the column by using a buffer with 250mM imidazole 
and shown on the figure as E1, E2 and E3. Elution fractions do not show the presence of 
PKR-KD protein. (B) Pull down assay of PKR-KD and His-MBP-STF. The fractions on the 
western blot were similar to the fractions described in panel A. (C) Pull down assay for 
PKR-KD only. PKR-KD protein was passed through the column (S) and the flow-through 
(FT) fraction was collected, washes W1, W2  had PKR-KD but elution fractions E1, E2 and 
E3 did not have any PKR-KD protein.  
 
 
5.2.3. In-vitro binding assays of E3 and PKR-KD 
In order to detect a physical interaction in the absence of dsRNA binding ability 
between monomeric or dimeric PKR-KD with E3[R131A], in vitro binding assays were 
conducted. Monomeric or dimeric PKR-KD was added to E3[R131A] protein in a molar ratio 
of 1:2 respectively along with 1mg/mL of AMP. This protein mixture was incubated for 1 
hour at 4°C and passed through SEC column. Different constructs of PKR-KD in pMBP28b+ 
vector were used for complex formation with E3 proteins. A shorter construct of PKR-KD 
(PKR-KD258_541) was used for the complex formation with E3[R131A] protein. It was 
observed in the SEC chromatogram that a protein with higher molecular weight in 
comparison to monomeric or dimeric PKR-KD or E3 protein eluted from the column (Fig. 
5.6, A). The elution volume of the protein mix eluted at 14.23 mL as compared to 
E3[R131A] that eluted at 14.91 mL, dimeric PKR-KD at 14.54 mLand monomeric PKR-KD 
at 15.53 mL. DLS was used to determine the estimated molecular weight of the protein 
complex,  which was approximately 90 KDa. The results from the SEC chromatograms 
suggested the formation of PKR-KD-E3 complex and this interaction does not depend on the 










Figure 5.6. Binding assay of monomeric PKR-KD258_541 with E3[R131A].  
(A) Chromatograms of E3-PKR-KD complex, E3 and PKR-KD proteins overlapped. The 
green chromatogram represents the E3-PKR-KD complex, the black chromatogram 
represents PKR-KD protein and the red chromatogram represents E3[R131A] protein. A 
shift in elution volume of the complex as compared to E3 and PKR-KD proteins was 
observed. (B) SDS-PAGE gel of the complex chromatogram shown in A. The fractions from 
the green chromatogram had both the proteins E3 and PKR-KD. Protein bands 
corresponding to the molecular weight of E3 (25 KDa) and PKR-KD proteins (33 KDa). (C) 
1% agarose gel with complex fractions from the green chromatogram shown in A. Agarose 
gel was run in 1X TAE buffer at 90 volts for 2 hours and protein migrated from negative to 
positive terminal. The migration of E3-PKR-KD complex was different from E3 and PKR-KD 





In order to test the fractions obtained from the SEC purification of the protein mix, 
SDS-PAGE and agarose gel. Protein bands corresponding to the molecular weight of both E3 
and PKR-KD were observed in the SEC fractions of the protein mix electrophoresed in SDS-
PAGE gel (Fig. 5.6, B). The SEC fractions of the protein mix were electrophoresed on the 
non-denaturing gel (1% agarose gel) shown in figure 5.6, C. Protein bands corresponding to 
the protein mix fractions migrated differently than E3 or PKR-KD protein when individually 
electrophoresed on the agarose gel. An excess of E3 protein was added not involved in the 
complex formation with PKR-KD. The results from the SDS-PAGE and agarose gels 
indicated the formation of a complex between E3 and PKR-KD. The complex formation 
between these proteins does not depend on their ability to bind to dsRNA. Based on the 
molecular weight calculations, the stoichiometry of the protein complex was estimated to be 
two molecules of E3 and one molecule of PKR-KD protein.  
Similar experiments were conducted with dimeric PKR-KD and E3[R131A] proteins 
to detect the interactions between these protein. A different construct of PKR-KD was used 
for the complex formation. PKR-KD258_551 H412N, C551A D338-350 in a GST vector was 
purified as a dimer and added in a 1:2 molar ratio with E3[R131A] protein. The protein 
mixture was passed through a SEC column. It was observed that the protein mixture eluted at 
15.03 mL in comparison to E3[R131A] that eluted at 14.91 mL and dimeric PKR-KD at 
14.68 mL (Fig. 5.7, A). The lack of shift in elution volume of the protein mixture compared 
to the individual proteins suggested that protein complex was not formed between dimeric 
PKR-KD and E3 as a higher molecular weight protein would have had a higher elution 





          
 
 
Figure 5.7. Binding assay of dimeric PKR-KD with E3[R131A].  
(A) Chromatograms of E3-PKR-KD complex, E3 and PKR-KD proteins overlapped. The 
black chromatogram represents the E3-PKR-KD complex, the green chromatogram 
represents PKR-KD protein and the red chromatogram represents E3[R131A] protein. No 
shift in elution volume of the complex was observed as compared to E3 and PKR-KD 
proteins. (B) SDS-PAGE gel of the complex chromatogram shown in A. The fractions from 
the black chromatogram had both the proteins E3 and PKR-KD. Protein bands 
corresponding to the molecular weight of E3 (25 KDa) and PKR-KD proteins (33 KDa). (C) 
1% agarose gel with complex fractions from the black chromatogram shown in A. Agarose 
gel was run in 1X TAE buffer at 90 volts for 2 hours and protein migrated from negative to 
positive terminal. The migration of E3-PKR-KD complex had similar pattern as individual 
E3 and PKR-KD proteins.  
 
SDS-PAGE and agarose gels were used to detect the SEC fractions obtained from the 
protein mix of E3 and dimeric PKR-KD. The SDS-PAGE gel of the protein mix SEC 




5.7, B). The agarose gel indicated that the SEC fractions from the protein mix migrated as E3 
and PKR-KD independent of each other, instead of a single protein band as observed in 
monomeric PKR-KD-E3 complex (Fig. 5.7, C). This suggested that dimeric PKR-KD and E3 
does not interact with each other to form a protein complex. The SEC chromatograms, SDS-
PAGE and agarose gels results combinedly suggested that dimeric PKR-KD and E3 proteins 
do not form a protein complex.  
A dimeric GST-tagged PKR-KD258_551 H412N, C551A protein was also used for 
binding assays with E3 proteins showed similar results as the dimeric PKR-KD. As a 
negative control, the N-terminal of PKR protein (PKR-N1_201 in GST vector) was used for 
binding assay with E3[R131A] protein. The GST tagged PKR-N1_201 was added to 
E3[R131A] and purified with SEC following a similar procedure. There was no interaction 
observed between PKR-N terminal and E3 proteins which was evident from the SEC 
chromatograms and SDS-PAGE gel (Fig 5.8).   
Unfortunately, the results from binding assays between monomeric PKR-KD258_541 
and E3[R131A] protein were not reproducible. Various constructs of PKR-KD in MBP or 
GST vectors were used for binding assays with E3 protein (Table 5.2). Protein interaction 
between these two protein was not observed for any of the conditions or different constructs 
of PKR-KD. The amount of salt in the buffer for complex purification in SEC was varied 
from 500 mM NaCl to 300 mM NaCl to improve the chances of protein interaction but it led 
to precipitation of E3 proteins and no complex formation. Similarly, different molar ratios for 






















     
 
Figure 5.8. Binding assay of dimeric GST-PKR-KD/GST-PKR-N with E3[R131A].  
(A) Chromatogram of E3-GST-PKR-KD complex. Both the proteins elute at different elution 
volumes based on their molecular weight suggesting a complex of these proteins was not 
formed. (B) Chromatogram of E3-GST-PKR-N complex. Both the proteins elute at different 
elution volumes based on their molecular weight suggesting a complex of these proteins was 
not formed. (C) SDS-PAGE gel of the fractions collected from chromatograms A and B. The 
protein mixture loaded on the SEC column was also ran on SDS-PAGE and labeled as S 
(supernatant). Fractions 24 and 30 were from chromatogram A and fractions 20 and 30 were 





Physical interaction between PKR and E3 proteins have been observed in yeast cells 
[13, 75].  A recent study has also shown the interaction between these two proteins in in-vitro 
pull down assays and in-vivo assays [14]. In this study, we demonstrated the interaction 




proteins. Pull down assays and complex formation with SEC assays were used for testing the 
interaction between PKR-KD and E3 proteins. PKR-KD activates by undergoing 
dimerization, hence it was important to determine whether the E3 proteins interacted with 
PKR-KD monomers or dimers after activation. It was determined that E3 mutants that lack 
dsRNA binding ability physically interacted with monomeric PKR-KD as observed in pull 
down assays and in vitro binding assays with SEC. A physical interaction between E3 and 
dimeric PKR-KD could not be observed either in pull down assays or binding assays which 
could be indicative of the absence of interaction between the E3 and dimeric PKR-KD. 
Because of the weak interaction between E3 and PKR-KD, it was considered that SEC was 





























E3 PROTEIN INHIBITS PKR ACTIVITY 
 
6.1. Introduction 
A study conducted on VACV E3 provided genetic evidence of E3 inhibiting PKR 
activity in yeast through potential complex formation [13]. A recent study on various E3 
mutants also reported a suppression of PKR activation in VACV infected HeLa cells. In 
this study, the authors measured the levels of PKR and eIF2a phosphorylation in HeLa 
cells infected with wildtype E3 or E3 mutant recombinant viruses [14]. Mechanism of E3 
inhibition of PKR activity had been predicted by Romano et al., and Sharp et al. These 
models suggested a physical interaction of E3 proteins to PKR dimers and a formation of 
inactive heterodimer, which eventually inhibits the PKR activity. The activation process 
of PKR starts with dimerization followed by autophosphorylation and phosphorylation of 
its substrate, eIF2a. E3 is known to affect the dimerization process but this mechanism 
has not been experimentally shown in any in vitro or in vivo studies.  
In this study, we attempted to understand the mechanism of E3 inhibition of PKR 
activity. The effect of E3 was analyzed on the catalytic domain or kinase domain of PKR 
rather than the full protein. It was predicted that E3 would inhibit the PKR-KD activity in 
the absence of dsRNA binding ability of both proteins. To test the prediction, various 




the kinase domain of PKR and the phosphorylation of PKR-KD and eIF2a was monitored. It 
was observed that E3 affected the autophosphorylation of PKR-KD and the phosphorylation 
of  eIF2a. These results contradict the previously proposed models of E3-PKR interaction, 
which suggested the importance of dsRNA binding for E3 to inhibit PKR activity.  
 
6.2.Results and Discussion 
 
6.2.1. Purification of yeast eIF2a  protein 
The yeast eIF2a4_175 protein was expressed in E.coli bacterial cells and purified using 
affinity chromatography and SEC. The fusion protein was purified without digesting the his- 
tag to aid in the in vitro phosphorylation assays along with E3 and PKR-KD proteins. The 
purified fusion protein had an expected molecular weight of 24 KDa (Fig. 6.1). The proteins 
expressed well and purified with an yield of 110 mg of total protein per liter of cell culture.  
                           
Figure 6.1. Size exclusion chromatogram and corresponding SDS-PAGE gel of His-




SEC profile of the fusion protein showed the presence of a predominant single peak and the 
fractions were electrophoresed on 15% SDS-PAGE gel. The fusion proteins were visualized 
on the gel at an expected molecular weight of approximately 24 KDa.  
 
6.2.2. E3 inhibits the autophosphorylation of PKR-KD 
The in vitro autophosphorylation assay was designed to determine the effect of E3 
proteins on the activation of PKR-KD proteins. Both monomeric (PKR-KD) and dimeric 
PKR-KD (GST-PKR-KD) proteins were utilized in the assay to understand the mechanism of 
E3 deactivation of PKR-KD. Various concentration of E3[R131A] were added to a protein 
mixture of monomeric/dimeric PKR-KD, eIF2a and ATP in a kinase reaction buffer. It was 
observed that E3 inhibited autophosphorylation of both monomeric and dimeric PKR-KD in 
a dose dependent manner (Fig. 6.2, Panel A). Increasing the dose of E3[R131A] in the 
reaction mixture eventually led to complete inhibition of autophosphorylation of PKR-KD 
and GST-PKR-KD. An amount of 13 µM of E3 protein completely inhibited the 
autophosphorylation of PKR-KD whereas the highest amount of E3 at 51 µM was required 
for complete inhibition of dimeric GST-PKR-KD. These assays were repeated three times for 
statistical significance and the gels were quantified using ImageJ software. Quantified data 
were plotted against the concentrations of E3 used in the assay (Fig. 6.3). E3 had an IC50 
value of  2.2 µM in case of PKR-KD whereas 9.5 µM for GST-PKR-KD. A significant 
difference (p < .001) was found between the inhibition of monomeric PKR-KD and dimeric 




    
 
 
Figure 6.2. In-vitro autophosphorylation assay indicating the inhibitory effect of E3[R131A] 
on PKR-KD/GST-PKR-KD activity.  
(A) Scanned radioactive gel displaying the phosphorylated PKR-KD and GST-PKR-KD and 
their inhibition with increase in E3 concentration. (B) The same scanned radioactive gel 
shown in A also displayed phosphorylated HiseIF2a4_175 and an inhibition of phosphorylated 
HiseIF2a4_175 with increase in E3 concentration was observed. (C) Radioactive scanned gel 
for control assay with individual proteins and 100 µM cold ATP supplemented with 5 µCi of 
g32P ATP. The 1st lane had E3[R131A] protein with ATP indicated no band, 2nd lane had 
HiseIF2a4_175 with ATP also indicated no band, 3rd and 4th lanes had PKR-KD and GST-
PKR-KD respectively with ATP that underwent autophosphorylation indicating the presence 
of g32P ATP.  
 
In order to detect the effect of E3 on phosphorylation of eIF2a, the phosphorylation 




eIF2a followed a similar pattern as observed in autophosphorylation of PKR-KD and GST-
PKR-KD by E3[R131A] (Fig. 6.2, Panel B).  
To test if the phosphorylation observed in the assay blots are due to the 
phosphorylation of PKR-KD and GST-PKR-KD, a control assay was conducted with 
individual proteins (E3[R131A], HiseIF2a4_175, PKR-KD and GST-PKR-KD) with 100 µM 
cold ATP supplemented with 5 µCi of g32P ATP. Radioactive signals were not observed in 
case of E3[R131A] and HiseIF2a4_175  indicating that these proteins do not undergo 
autophosphorylation simply in the presence of ATP (Fig. 6.2, Panel C). PKR-KD and GST-
PKR-KD on the other hand underwent phosphorylation validating the results obtained in the 
above mentioned autophosphorylation assays.   
Based on the results from the in vitro autophosphorylation assay, it was suggested 
that E3 proteins inhibit the autophosphorylation of PKR-KD and without the requirement of 
dsRNA binding. The difference in inhibitory effect of E3 on PKR-KD and GST-PKR-KD 
was indicative of two pathways that E3 followed for PKR-KD inhibition: first with 
monomeric PKR-KD which is in the process of dimerization and second with activated and 
dimerized GST-PKR-KD. A physical interaction between E3 and monomeric PKR-KD had 
already been established and the results from monomeric PKR-KD autophosphorylation 
assay together support the model that E3 physically binds to monomeric PKR-KD which 
disrupts its dimerization process and thus autophosphorylation and phosphorylation of eIF2a. 
Similarly, a physical interaction between E3 and dimeric PKR-KD was not observed which 
could be due to lack of interaction or a very weak interaction between these two proteins. 
The autophosphorylation assay displayed a lower inhibition effect of E3 on dimeric GST-




disrupts the already dimerized PKR-KD, inhibits its autophosphorylation and thus 




Figure 6.3. Quantitative analysis of in-vitro autophosphorylation assay with E3[R131A] and 
PKR-KD/GST-PKR-KD.  
(A) The graph represents the quantitative analysis of the autophosphorylation gels conducted 
in triplicates. The densitometry data from the gels in Figure 6.2 were obtained using ImageJ 
software. The x-axis represents the concentration of E3[R131A] used in the assays and the y-
axis represents the percent PKR-KD/GST-PKR-KD activity. (B) The IC50 values of the 
triplicate assays performed for PKR-KD/GST-PKR-KD with E3 protein. IC50 values were 
calculated using GraphPad Prism version 5.0 for Windows, GraphPad Software, La Jolla 
California USA, www.graphpad.com. The p-value for the difference in inhibition of PKR-KD 





6.2.3. E3 inhibits the phosphorylation of eIF2a  by PKR-KD 
In vitro kinase assays were performed to determine the effect of E3 on the 
phosphorylation of eIF2a without the dsRNA binding ability of either E3 or PKR-KD. PKR-
KD proteins purify in a weak equilibrium of monomeric and dimeric state and upon long 
term storage in -80°C, the monomeric fractions had converted to PKR-KD dimers. Hence, to 
combat this problem, all the in-vitro kinase assays were performed with freshly purified E3 
and PKR-KD proteins. Dimeric or trimeric E3 fractions were used for the assays to ensure 
the inhibitory effects of E3 on PKR-KD activity. These criteria and conditions were followed 
for all the in-vitro kinase assays to remain consistent through-out.    
The E3[R131A] protein inhibited phosphorylation of His-eIF2a4_175 in case of both 
monomeric PKR-KD and dimeric GST-PKR-KD. Consistent with the His-eIF2a4_175 
phosphorylation results obtained in autophosphorylation assay, inhibition of His-eIF2a4_175 
phosphorylation was observed more in monomeric PKR-KD than dimeric GST-PKR-KD 
(Fig. 6.4, Panel A). A different western blot with the same in vitro kinase assay reactions 
were blotted with anti-His antibody to demonstrate the loading control in these assays. As 
observed in figure 6.4, an equal amount of His-eIF2a4_175 was added to each reactions and 
the inhibition of His-eIF2a4_175 phosphorylation was due to increased concentration of 
E3[R131A] protein. An amount of 26 µM of E3 protein inhibited the phosphorylation of 
HiseIF2a4_175 completely in monomeric PKR-KD reactions whereas 52 µM of E3 was 
needed for inhibition in case of dimeric GST-PKR-KD. The calculated IC50 value for 
E3[R131A] protein for inhibiting phosphorylation of His-eIF2a4_175 in an assay with 
monomeric PKR-KD was 5.4 µM and for dimeric GST-PKR-KD was 6.5 µM. A p-value of 




between E3[R131A] inhibition of His-eIF2a4_175 phosphorylation led by PKR-KD and GST-
PKR-KD (Fig. 6.5).  
To validate the inhibition of phosphorylated His-eIF2a4_175 by E3[R131A] proteins, a 
control assay was performed similar to the in vitro kinase assay with Bovine Albumin Serum 
(BSA) protein instead of E3. BSA was unable to inhibit the phosphorylation of HiseIF2a4_175 
suggesting that the inhibition observed in these assays represent the actual result of E3 and 
PKR-KD interactions (Fig. 6.4, Panel B). Higher oligomers of E3 (10-15 E3 molecules) or 




Figure 6.4. In-vitro kinase assay indicating the inhibitory effect of E3[R131A] on 
phosphorylation of HiseIF2a4_175 led by PKR-KD/GST-PKR-KD and control in-vitro assay 
with BSA.  
(A) Western blot of in-vitro assay of E3[R131A] protein shows the inhibition of 
HiseIF2a4_175 phosphorylation with increased concentration of E3 and  blotted with anti-
phospho-serine51-eIF2a antibody. The 1st six reactions are assembled with monomeric 
PKR-KD and the 2nd six reactions with dimeric GST-PKR-KD with different concentrations 
of E3[R131A] protein. The panel underneath is a separate blot that represents the loading 
control blotted with anti-His antibody with protein reactions used in the in vitro kinase 
assays. (B) Control assay with BSA protein instead of E3 shows no inhibition of 




blotted with anti-phospho-serine51-eIF2a antibody and the loading control gel underneath 
was blotted with anti-His antibody.  
 
 
Figure 6.5. Quantitative analysis of in-vitro kinase assay to measure the inhibition of 
HiseIF2a4_175 phosphorylation by E3[R131A].  
(A) The graph represents the quantitative analysis of the western blots conducted in 
triplicates. The densitometry data from the gels in figure 6.4 were obtained using ImageJ 
software. The x-axis represents the concentration of E3[R131A] used in the assays and the y-
axis represents the percent PKR-KD/GST-PKR-KD activity as a correlation to HiseIF2a4_175 
phosphorylation. (B) The IC50 values of the triplicate assays performed for PKR-KD/GST-
PKR-KD with E3 protein. IC50 values were calculated using GraphPad Prism version 5.0 
for Windows, GraphPad Software, La Jolla California USA, www.graphpad.com. The p-
value for the difference in inhibition of PKR-KD and GST-PKR-KD by E3 was calculated 
using GraphPad QuickCalcs Web site.  
 
To test a difference in the ability to inhibit the phosphorylation of HiseIF2a4_175, a 
different E3[F148A] mutant was used. Results showed that E3[F148A] inhibited 
phosphorylation of HiseIF2a4_175 by PKR-KD and GST-PKR-KD (Fig. 6.6). An amount of 




HiseIF2a4_175 for both PKR-KD and GST-PKR-KD reactions. The calculated IC50 values of 
E3[F148A] for these assays were 6.3 µM and 6.5 µM for PKR-KD and GST-PKR-KD 
respectively (Fig. 6.7). The p-value was calculated to be more than 0.05 which demonstrated 




Figure 6.6. In-vitro kinase assay indicating the inhibitory effect of E3[F148A] on 
phosphorylation of HiseIF2a4_175 led by PKR-KD/GST-PKR-KD.  
Western blot of in-vitro assay of E3[F148A] protein shows the inhibition of HiseIF2a4_175 
phosphorylation with increased concentration of E3 and  blotted with anti-phospho-serine51-
eIF2a4 antibody. The 1st six reactions are assembled with monomeric PKR-KD and the 2nd 
six reactions with dimeric GST-PKR-KD with different concentrations of E3[F148A] protein. 
The panel underneath is a separate blot that represents the loading control blotted with anti-
His antibody with protein reactions used in the in vitro kinase assays. 
 
E3[R131A] showed a complete inhibition of phosphorylated HiseIF2a4_175 at a 
concentration of 26 µM for monomeric PKR-KD reactions whereas for E3[F148A] protein it 
required 52 µM. The IC50 values for these assays were 5.4 µM and 6.3 µM for E3[R131A] 
and E3[F148A] respectively. The difference had statistical significance as the p-value was 
more than 0.05. Similarly, a comparison was made for the effect of E3[R131A] and 




There were no significant differences found between the two E3 mutants for GST-PKR-KD 
reactions (p-value > 0.05, 6.2 µM for E3[R131A], 5.4 µM for E3[F148A]).  
Based on the comparisons of the effect of E3[R131A] and E3[F148A] on the 
phosphorylation of eIF2a by PKR-KD or GST-PKR-KD, it was inferred that phenyl alanine 
residue at position 148 in E3 proteins could be an essential amino acid required for the 




Figure 6.7. Quantitative analysis of in-vitro kinase assay to measure the inhibition of 
HiseIF2a4_175 phosphorylation by E3[F148A].  
(A) The graph represents the quantitative analysis of the western blots conducted in 
triplicates. The densitometry data from the gels in figure 6.6 were obtained using ImageJ 
software. The x-axis represents the concentration of E3[F148A] used in the assays and the y-
axis represents the percent PKR-KD/GST-PKR-KD activity as a correlation to HiseIF2a4_175 
phosphorylation. (B) The IC50 values of the triplicate assays performed for PKR-KD/GST-
PKR-KD with E3 protein. IC50 values were calculated using GraphPad Prism version 5.0 




value for the difference in inhibition of PKR-KD and GST-PKR-KD by E3 was calculated 
using GraphPad QuickCalcs Web site.  
 
6.2.4. N and C-terminals of E3 are required for PKR-KD inhibition  
The predicted models for E3 and PKR interactions had advocated the importance of 
both N and C-terminals of E3 protein. These studies have shown the interaction of E3 and 
PKR (in-vivo coimmunoprecipitation assay) was dependent on both N and C-terminal of E3 
[13, 75]. A physical interaction between E3 and PKR-KD has already been established in this 
study. This result indicates that the dsRNA binding N-terminal domain of PKR is dispensable 
for PKR and E3 interaction contrary to the proposed model (Fig. 2.12). To resolve this 
discrepancy, in vitro kinase assays were conducted with E3[R131A] N-terminal (amino acids 
1-79) and C-terminal (amino acids 81- 190) protein individually.  
The results from in vitro kinase assay with E3[R131A] N-terminal protein 
demonstrated a lack of inhibition of His-eIF2a4_175 phosphorylation by monomeric PKR-KD. 
This result was in accordance with the prediction that both N and C-terminals of E3 are 
required for its activity. But the results for the GST-PKR-KD reactions displayed inhibition 
of His-eIF2a4_175 phosphorylation with an increase in E3[R131A] N-terminal protein 
concentration (Fig. 6.8). A complete inhibition of HiseIF2a4_175 was observed at 26 µM of 








Figure 6.8. In-vitro kinase assay indicating the inhibitory effect of E3[R131A] N-terminal 
protein on phosphorylation of HiseIF2a4_175 led by PKR-KD/GST-PKR-KD.  
Western blot of in-vitro assay of E3[R131A] N-terminal protein shows no inhibition of 
HiseIF2a4_175 phosphorylation led by PKR-KD whereas inhibition in case of GST-PKR-KD 
with increased concentration of E3. The membranes were blotted with anti-phospho-
serine51-eIF2a antibody. The 1st six reactions are assembled with monomeric PKR-KD and 
the 2nd six reactions with dimeric GST-PKR-KD with different concentrations of E3[R131A] 
N-terminal protein. The panel underneath is a separate blot that represents the loading 
control blotted with anti-His antibody with protein reactions used in the in vitro kinase 
assays. 
 
The results from the in vitro kinase assay of E3[R131A] N terminal protein suggested 
that the interaction of dimeric PKR-KD with E3 N terminal disrupted the PKR-KD dimers 
leading to inhibition of PKR-KD autophosphorylation and eventually inhibition of His-







Figure 6.9. Quantitative analysis of in-vitro kinase assay to measure the inhibition of 
HiseIF2a4_175 phosphorylation by E3[R131A] N terminal.  
(A) The graph represents the quantitative analysis of the western blots conducted in 
triplicates. The densitometry data from the gels in figure 6.8 were obtained using ImageJ 
software. The x-axis represents the concentration of E3[R131A] N protein used in the assays 
and the y-axis represents the percent GST-PKR-KD activity as a correlation to HiseIF2a4_175 
phosphorylation. (B) The IC50 values of the triplicate assays performed for GST-PKR-KD 
with E3 protein. IC50 values were calculated using GraphPad Prism version 5.0 for 
Windows, GraphPad Software, La Jolla California USA.  
 
A binding assay was conducted between E3[R131A] N and dimeric/monomeric PKR-
KD protein to understand the inhibitory effect of E3 N terminal on dimeric GST-PKR-KD 
activity. A protein mix of E3[R131A]N and PKR-KD protein was passed through a SEC 
column. Both dimeric and monomeric PKR-KD failed to physically interact with E3 N 
terminal protein (Fig. 6.10 & 6.11). Two main peaks were observed in the SEC for both 
monomeric PKR-KD and dimeric PKR-KD complex formation assay with E3N protein. The 




suggesting a non-formation of complex. The results from SEC did not reveal an interaction 
between the two proteins. However, weak protein-protein interactions are difficult to be 
measured in size exclusion chromatography method, which could be a possible reason for the 
non-formation of complex between E3 N and dimeric PKR-KD.   
 
                  
 
Figure 6.10. Size exclusion chromatogram of interactions between E3[R131A] N  and 
monomeric PKR-KD with the corresponding SDS-PAGE gel of the complex formation assay.  
(A) Comparison of the chromatograms for E3[R131A] N protein (Blue), PKR-KD (Red) and 
complex (Green). The corresponding elution volumes are mentioned along the peaks. (B) 
SDS-PAGE gel of fractions from the E3[R131A] N and PKR-KD complex SEC. Fractions 






               
Figure 6.11. Size exclusion chromatogram of interactions between E3[R131A] N  and 
dimeric PKR-KD with the corresponding SDS-PAGE gel of the complex formation assay.  
(A) Comparison of the chromatograms for E3[R131A] N protein (Orange), dimeric PKR-KD 
(Green) and complex (Black). The corresponding elution volumes are mentioned along the 
peaks. (B) SDS-PAGE gel of fractions from the E3[R131A] N and PKR-KD complex SEC. 
Fractions from the main two peaks were electrophoresed on a 15% SDS-PAGE gel.  
 
Similar to the E3 N-terminal, in-vitro kinase assay of the C-terminal of E3[R131A] 
protein with PKR-KD and GST-PKR-KD was conducted which displayed no inhibition in 




monomeric or dimeric PKR-KD activity which was observed by the identical 




Figure 6.12. In-vitro kinase assay indicating the inhibitory effect of E3[R131A] C-terminal 
protein on phosphorylation of HiseIF2a4_175 led by PKR-KD/GST-PKR-KD.  
Western blot of in-vitro assay of E3[R131A] C-terminal protein shows no inhibition of 
HiseIF2a4_175 phosphorylation led by PKR-KD and GST-PKR-KD. The membranes were 
blotted with anti-phospho-serine51-eIF2a antibody. The 1st six reactions are assembled with 
monomeric PKR-KD and the 2nd six reactions with dimeric GST-PKR-KD with different 
concentrations of E3[R131A] C-terminal protein. The panel underneath is a separate blot 
that represents the loading control blotted with anti-His antibody with protein reactions used 
in the in vitro kinase assays. 
 
A binding assay was conducted to detect the interactions between E3[R131A] C-
terminal protein and monomeric PKR-KD. The results indicated that a non-interaction of 
these proteins (Fig. 6.13). Comparison of the chromatogram of complex of E3 C and PKR-
KD protein with their individual SEC purification chromatograms indicated that these 
proteins do not interact. A broader peak of the chromatogram had an elution volumes of 
14.53 mL and 15.26 mL which corresponded to the elution volumes of dimeric and 
monomeric PKR-KD respectively whereas the sharp 2nd peak had an elution volume closer to 
E3[R131A] C protein. There was no shift in elution volumes and separate peaks 




results from the complex formation assay and in-vitro kinase assay confirmed that the C-
terminal of E3 does not physically interact with PKR-KD in the absence of E3 N-terminal.  
 
         
 
Figure 6.13. Size exclusion chromatogram of interactions between E3[R131A] C  and 
monomeric PKR-KD with the corresponding SDS-PAGE gel of the complex formation assay.  
(A) Comparison of the chromatograms for E3[R131A] C protein (Orange), PKR-KD (Green) 
and complex (Black). The corresponding elution volumes are mentioned along the peaks. (B) 
SDS-PAGE gel of fractions from the E3[R131A] C and PKR-KD complex SEC. Fractions 
from the main two peaks were electrophoresed on a 15% SDS-PAGE gel. 
 
In order to detect the effects of E3 N and E3 C together on PKR-KD activity, 
E3[R131A] N and E3[R131A] C were added in a 1:1 molar ratio and this protein mixture 




two individual proteins rather than a full length E3 protein and the inhibition pattern would 
be similar to what was observed in each individual case. The results did not uphold the 
predictions. It was observed that no inhibition of the phosphorylation of His-eIF2a4_175 
occurred in either monomeric PKR-KD or dimeric GST-PKR-KD even for different 
concentrations of the E3 N-E3 C mix (Fig. 6.14).  
       
 
 
Figure 6.14. In-vitro kinase assay indicating the inhibitory effect of an equal mix of 
E3[R131A] N and C-terminal protein on phosphorylation of HiseIF2a4_175 led by PKR-
KD/GST-PKR-KD.  
Western blot of in-vitro assay of E3[R131A] N and C-terminal protein shows no inhibition of 
HiseIF2a4_175 phosphorylation led by PKR-KD and GST-PKR-KD. The membranes were 
blotted with anti-phospho-serine51-eIF2a antibody. The 1st six reactions are assembled with 
monomeric PKR-KD and the 2nd six reactions with dimeric GST-PKR-KD with different 
concentrations of E3[R131A] N and C-terminal protein. The panel underneath is a separate 
blot that represents the loading control blotted with anti-His antibody with protein reactions 
used in the in vitro kinase assays. 
 
The in vitro kinase assay for the protein mixture was repeated to confirm the results 
obtained. Results showed no inhibition of phosphorylated HiseIF2a4_175  by PKR-KD or 
GST-PKR-KD, apart from a slight inhibition that was observed with 52 µM of the protein 
mix in the PKR-KD reaction. The E3 N protein individually had inhibited the activity of 




explanation for this phenomenon could be that E3 C protein binds to E3 N in the protein 
mixture which makes the binding surface of E3 N interacting with dimeric PKR-KD 
inaccessible. This leads to no inhibition of GST-PKR-KD activity by E3 N as observed 
earlier.  
In order to detect an interaction between E3 N and E3 C proteins, a binding assay was 
conducted. Equal molar ratio of E3[R131A] N and E3[R131A] C protein were added and 
passed through a SEC column. It was observed that the SEC chromatogram of E3 N-E3 C 
protein mix showed a main peak with a shoulder (Fig. 6.15). The elution volume of the main 
peak corresponded with that of E3 N protein with a minor shift to the left whereas the 
shoulder had an elution volume that corresponded to E3 C protein. The SDS-PAGE gel 
exhibited few fractions of the main peak with both E3 N and E3 C proteins. Although the 
SDS-PAGE gel had fractions with both proteins, it could be due to an overlap of elution 
volumes because of comparable molecular weight. Based on the comparison of 
chromatograms from protein mix and individual proteins and the SDS-PAGE gel, it was 







Figure 6.15. Size exclusion chromatogram of interactions between E3[R131A] N  and 
E3[R131A] C protein with the corresponding SDS-PAGE gel of the complex formation 
assay.  
(A) Comparison of the chromatograms for E3[R131A] N protein (Orange), E3[R131A] C 
(Green) and complex (Black). The corresponding elution volumes are mentioned along the 
peaks. (B) SDS-PAGE gel of fractions from the E3[R131A] N and E3[R131A] C complex 
SEC. Fractions from the main peaks were electrophoresed on a 15% SDS-PAGE gel. 
 
6.2.5. E3 double mutants inhibit PKR-KD activity 
In a recent study, a GST pull down assay with endogenous PKR in HeLa cells was 




interaction was found between these proteins [14]. As the E3CD25 protein was known to not 
interact with PKR, it was used as a negative control to test the robustness of the in vitro 
kinase assays in this study. The results of the in vitro kinase assay demonstrated that E3CD25 
did not inhibit the phosphorylation of HiseIF2a4_175 by monomeric PKR-KD and dimeric 
GST-PKR-KD (Fig. 6.16). These results suggested that E3CD25 does not physically interact 




Figure 6.16. In-vitro kinase assay indicating the inhibitory effect of E3CD25 protein on 
phosphorylation of HiseIF2a4_175 led by PKR-KD/GST-PKR-KD.  
Western blot of in-vitro assay of E3CD25 protein shows no inhibition of HiseIF2a4_175 
phosphorylation led by PKR-KD and GST-PKR-KD. The lighter signal in case of PKR-KD 
reactions were due to the quality of protein used as compared to GST-PKR-KD. The 
membranes were blotted with anti-phospho-serine51-eIF2a antibody. The 1st six reactions 
are assembled with monomeric PKR-KD and the 2nd six reactions with dimeric GST-PKR-
KD with different concentrations of E3CD25 protein. The panel underneath is a separate blot 
that represents the loading control blotted with anti-His antibody with protein reactions used 
in the in vitro kinase assays. 
 
Authors in the same study as mentioned earlier, also noted that single mutants of E3 
(I110A and F159A) physically interact with PKR, but do not inhibit PKR activity [14]. 
Double mutants incorporating these mutations were developed in E3 protein. These double 
mutants were tested for their ability to inhibit PKR-KD activity. An inhibition of 




increased concentration of E3[R131AI110A] protein (Fig. 6.17). The inhibition was higher in 
case of the GST-PKR-KD than PKR-KD reactions. A concentration of 13 µM of E3 protein 




Figure 6.17. In-vitro kinase assay indicating the inhibitory effect of E3[R131AI110A] protein 
on phosphorylation of HiseIF2a4_175 led by PKR-KD/GST-PKR-KD.  
Western blot of in-vitro assay of E3[R131AI110A] protein shows inhibition of HiseIF2a4_175 
phosphorylation led by PKR-KD and GST-PKR-KD. The membranes were blotted with anti-
phospho-serine51-eIF2a antibody. The 1st six reactions are assembled with monomeric 
PKR-KD and the 2nd six reactions with dimeric GST-PKR-KD with different concentrations 
of E3[R131AI110A] protein. The panel underneath is a separate blot that represents the 
loading control blotted with anti-His antibody with protein reactions used in the in vitro 
kinase assays. 
 
 The E3[R131AI110A] protein had a calculated IC50 value of 3.6 µM for inhibition of 
monomeric PKR-KD activity whereas only 1.6 µM for dimeric GST-PKR-KD (Fig. 6.18). 
The difference in the inhibitory ability of E3[R131AI110A] for PKR-KD and GST-PKR-KD 





       
 
 
Figure 6.18. Quantitative analysis of in-vitro kinase assay to measure the inhibition of 
HiseIF2a4_175 phosphorylation by E3[R131AI110A].  
(A) The graph represents the quantitative analysis of the western blots conducted in 
triplicates. The densitometry data from the gels in figure 6.17 were obtained using ImageJ 
software. The x-axis represents the concentration of E3[R131AI110A] used in the assays and 
the y-axis represents the percent PKR-KD/GST-PKR-KD activity as a correlation to 
HiseIF2a4_175 phosphorylation. (B) The IC50 values of the triplicate assays performed for 
PKR-KD/GST-PKR-KD with E3 protein. IC50 values were calculated using GraphPad 
Prism version 5.0 for Windows, GraphPad Software, La Jolla California USA, 
www.graphpad.com. The p-value for the difference in inhibition of PKR-KD and GST-PKR-
KD by E3 was calculated using GraphPad QuickCalcs Web site.  
 
Due to the strong inhibition of GST-PKR-KD activity by E3[R131AI110A] mutant as 
observed in the in vitro kinase assays, these proteins were tested for protein-protein 




KD. The SEC chromatogram of the protein complex showed the presence of two main peaks 
with elution volumes of 14.40 mL and 15.51 mL. Comparison of complex SEC 
chromatogram with chromatograms of individual proteins demonstrated the two main peaks 
corresponding to dimeric PKR-KD and E3[R131AI110A] protein (Fig. 6.19). This 
comparison suggested that a complex was not formed between the two proteins but a slight 
shift of the 1st peak to a higher elution volume as compared to dimeric PKR-KD could 
possibly be due to the formation of a higher molecular weight complex. The main peak 
fractions from the SEC purification of complex was electrophoresed on a 15% SDS-PAGE 
gel showed the presence of both proteins in all fractions implying either a complex formation 
between the two proteins or an overlap of elution peaks due to similar molecular weight that 






               
 
Figure 6.19. Size exclusion chromatogram of interactions between E3[R131AI110A] and 
dimeric PKR-KD with the corresponding SDS-PAGE gel of the complex formation assay.  
(A) Comparison of the chromatograms for E3[R131AI110A] protein (Orange), dimeric PKR-
KD (Green) and complex (Black). The corresponding elution volumes are mentioned along 
the peaks. (B) SDS-PAGE gel of fractions from the E3[R131AI110A] and PKR-KD complex 
SEC. Fractions from the main two peaks were electrophoresed on a 15% SDS-PAGE gel. 
 
Another double mutant of E3 (R131A F159A) was also tested for its effect on PKR 
activity. An in-vitro kinase assay was conducted with E3[R131AF159A] protein with PKR-
KD and GST-PKR-KD to detect the effect of E3 on phosphorylation of eIF2a, a substrate of 




monomeric PKR-KD and dimeric GST-PKR-KD with increasing concentrations of 
E3[R131AF159A] protein (Fig. 6.20). A concentration of 26 µM of E3[R131AF159A] was 
required for complete inhibition of HiseIF2a4_175 phosphorylation by PKR-KD whereas 13 
µM for GST-PKR-KD.   
     
 
Figure 6.20. In-vitro kinase assay indicating the inhibitory effect of E3[R131AF159A] 
protein on phosphorylation of HiseIF2a4_175 led by PKR-KD/GST-PKR-KD.  
Western blot of in-vitro assay of E3[R131AF159A] protein shows inhibition of HiseIF2a4_175 
phosphorylation led by PKR-KD and GST-PKR-KD. The membranes were blotted with anti-
phospho-serine51-eIF2a antibody. The 1st six reactions are assembled with monomeric 
PKR-KD and the 2nd six reactions with dimeric GST-PKR-KD with different concentrations 
of E3[R131AF159A] protein. The panel underneath is a separate blot that represents the 
loading control blotted with anti-His antibody with protein reactions used in the in vitro 
kinase assays. 
 
E3[R131AF159A] protein had a calculated IC50 value of 4 µM for inhibiting 
phosphorylation of HiseIF2a4_175 by PKR-KD whereas a 2.6 µM for GST-PKR-KD reactions 
(Fig. 6.21). The difference between the effect of E3[R131AF159A] protein on monomeric 








Figure 6.21. Quantitative analysis of in-vitro kinase assay to measure the inhibition of 
HiseIF2a4_175 phosphorylation by E3[R131AF159A].  
(A) The graph represents the quantitative analysis of the western blots conducted in 
triplicates. The densitometry data from the gels in figure 6.20 were obtained using ImageJ 
software. The x-axis represents the concentration of E3[R131AF159A] used in the assays 
and the y-axis represents the percent PKR-KD/GST-PKR-KD activity as a correlation to 
HiseIF2a4_175 phosphorylation. (B) The IC50 values of the triplicate assays performed for 
PKR-KD/GST-PKR-KD with E3 protein. IC50 values were calculated using GraphPad 
Prism version 5.0 for Windows, GraphPad Software, La Jolla California USA, 
www.graphpad.com. The p-value for the difference in inhibition of PKR-KD and GST-PKR-
KD by E3 was calculated using GraphPad QuickCalcs Web site.  
 
Both the E3 double mutants had a strong inhibitory effect on the activity of PKR-KD 
and GST-PKR-KD. The inhibition was observed more in case of dimeric GST-PKR-KD as 
compared to monomeric PKR-KD. The difference in the inhibitory effect of both E3 double 
mutants in case of PKR-KD activity was compared and found not to be statistically 




difference between both the double mutants was highly significant with a p-value less than 
0.05. These results indicated E3[R131AI110A] protein had the maximum impact on PKR-
KD/GST-PKR-KD activity as compared to single mutants and other constructs of E3 used in 
various in-vitro kinase assays. It could be explained by suggesting that the double mutations 
on E3 protein could structural alter the protein to enhance its binding ability to PKR-KD 
proteins as compared to other E3 constructs.  
A summary of all the in-vitro kinase assays performed in this study are compiled in a 
table along with their functional characteristics (Table 6.1). The biological properties listed in 
the table were obtained from this study and a recent study conducted by Dueck, 2015 [14]. 
 
Table 6.1. Results of in-vitro kinase assays for all the different E3 constructs along with their 









In an effort to understand the mechanism of E3 inhibition of PKR-KD activity, we 
conducted various in vitro kinase assays. All these experiments were conducted in the 
absence of dsRNA binding ability for both proteins. The results from the in vitro kinase 
assays demonstrated that E3 could inhibit PKR-KD activity by disrupting the 
autophosphorylation of PKR-KD, which affected the phosphorylation of eIF2a. While 
conducting in vitro kinase assays, it was observed that aggregated E3 proteins did not inhibit 
PKR-KD activity. This was an important observation, which suggested that only lower 
molecular weight oligomers of E3 could inhibit PKR-KD activity in vitro. In cells, E3 
remains in an aggregated state, which increases the multivalence useful for a tighter binding 
with PKR.  
Models previously proposed on the interaction of E3 and PKR  suggested that a 
protein-protein contact occurred between the DRBD domains of PKR and E3 with a mutual 
binding to the same dsRNA that stabilized the complex of PKR-E3-dsRNA [13, 75]. In this 
study, we showed that full length E3 physically interacted with the C-terminal of PKR and 
this interaction occurred without the mutual binding of dsRNA to both proteins. The physical 
interaction between the two proteins was important for E3 to inhibit the autophosphorylation 
of PKR-KD. Previous models also suggested that the N-terminal of E3 interacts with the C-
terminal of PKR along with interactions between the DRBDs of both proteins. Interactions 
between E3 and PKR required dsRNA [13]. In this study, an interaction between N-terminal 
of E3 and C-terminal of PKR could not be established. Results from the in vitro assays on 




inhibited dimeric PKR-KD activity. A similar inhibition of dimeric PKR-KD activity by E3 
N protein has been claimed in a previous study but with no experimental evidence [13].  
An importance of the N and C-terminals of E3 protein has been emphasized in 
previous predicted models of E3-PKR interactions. In this study, we also demonstrated that 
E3 protein required both its N and C terminals to inhibit PKR-KD activity. We established 
that the physical interaction between E3 and PKR-KD is mandatory for E3 to inhibit PKR-
KD activity. In vitro assays conducted on E3CD25, which has been shown to physically not 
bind to PKR in vivo [14] and PKR-KD in vitro (in this study), and PKR-KD showed no 
inhibition of PKR-KD activity.  
In vitro assay with E3[F148A] showed different results than E3[R131A] mutant 
suggesting an essential nature of the amino acid 148 for E3 to inhibit PKR-KD activity. Both 
the E3 double mutants had a strong inhibitory effect on the activity of monomeric and 
dimeric PKR-KD. The inhibition was observed more in case of dimeric as compared to 
monomeric PKR-KD. E3[R131AI110A] protein had the maximum impact on PKR-KD 
activity as compared to single mutants and other constructs of E3 used in various in-vitro 
kinase assays. It could be explained by suggesting that the double mutations on E3 protein 
could structural alter the protein to enhance its binding ability to PKR-KD proteins as 
compared to other E3 constructs.  
Overall, this study was the first time to demonstrate the mechanism of E3 inhibition 
of PKR-KD by conducting in vitro studies. This study also demonstrated the inessentiality of 
dsRNA binding for E3 and PKR-KD to physically interact with each other and E3 to inhibit 






CRYSTALLIZATION OF VACV E3 PROTEIN 
 
7.1. Introduction 
VACV E3 proteins have been studied for more than 15 years in a quest for 
understanding its functional and structural aspects. This protein affects the innate immune 
response of the host cell in multiple ways and that makes it an important protein of 
interest for scientist in this field. Although a well-studied protein, there are still a lot of 
information missing about E3 and the structure of this protein is one among many. E3 
proteins stay in an aggregated form in the cytoplasm of the host cells. Aggregation helps 
E3 protein to enter into the nuclear compartment of the host cells by either directly 
altering the physical state of the protein or indirectly preventing the export of cytoplasmic 
E3 proteins into the nucleus [15]. Structural analysis of E3 proteins has been difficult due 
to the problem of aggregation. The idea of using protein engineering to alleviate 
aggregation towards structural studies was derived from a recent success on a non-related 
difficult protein project conducted by a group in Baylor College of Medicine, Texas [17]. 
Based on the success achieved in the above mentioned study, it was hypothesized that 
single/double point mutations of E3 proteins might mitigate the problem of aggregation 





Expression and purification of single (E3[R131A]) and double mutants (E3[R131AI110A]) 
of E3 did not completely eliminate the problem of protein aggregation but obtained lower 
oligomeric state stable proteins that could be used for crystallization. This chapter covers the 
early attempts at purifying stable E3 proteins and setting up crystallization conditions using 
various screening kits.  
 
7.2. Results and Discussion 
 
7.2.1. Crystals of E3[R131AI110A] 
 The wildtype E3 proteins purify as aggregates which could not be used for structural 
analysis hence surface mutations on E3 were introduced to reduce or abrogate the problem of 
aggregation. Single mutant E3[R131A] reduced aggregation and purified as lower oligomeric 
protein but these protein were not stable. At higher concentration, the E3[R131A] protein 
fractions tended to form higher oligomers or aggregates. Quite contrary to the single mutant, 
a double mutant of E3 (R131AI110A) formed dimers even at higher protein concentration. 
This protein was purified to more than 95% purity and verified to be homogeneous. The 
crystal trays were scanned regularly for crystal formation as per the schedule. Almost 80 
percent of the droplets had protein precipitate without any crystals. Out of the 288 conditions, 
crystal like structures were observed in one of the droplet after more than a month (Fig. 7.1). 
The crystallization condition was from the BCS screen kit (MD1-104, Molecular 
Dimensions) and had 0.15M Sodium chloride, 28% v/v PEG Smear Medium. Izit crystal dye 
(Hampton Research) was used for differentiating protein crystals from salt crystals. Izit is a 




channels in the protein crystal and turn the crystal blue. But in case of salt crystals, due to the 
lack of large solvent channels, the crystal does not turn blue. Izit dye was added to the 
droplet containing the crystals. The crystals did not turn blue suggesting the formation of salt 
crystals rather than protein. Thin, needle shaped blue crystals appeared after the addition of 
the Izit dye which were crystals of the dye present in Izit. This occurs in crystallization 
reagents with a high relative supersaturation (Fig. 7.1). 
  
 
Figure 7.1. Crystallization droplet of E3[R131AI110] for one condition in the BCS screen 
kit.  
(A) The droplet of E3[R131AI110A] with 0.15M Sodium chloride, 28% v/v PEG Smear 
Medium reagent showed the presence of salt crystals. (B) A closer look at the salt crystals. 
(C) The same droplet as shown in A but with Izit dye to identify the crystals. The salt crystals 
did not turn blue and needle like crystals of the Izit dye were formed in the reagent.  
 
7.2.2. Predicted structure of E3 
The secondary structure and a 3D model of VACV E3 protein were predicted using 
an online program, I-TASSER [87-89]. The amino acid sequence of E3 protein was provided 
and the software projected the best-fitted secondary structure prediction (Fig. 7.2). The 
sequence-based prediction of secondary structure of E3 was conducted by PSSpred (Protein 




training algorithm for accurate protein secondary structure prediction. The N-terminal of E3 
(amino acids 1-79), the Z-DNA binding domain consisted mostly of coils and a-helices 
based on the predictions. The crystal structure of the N-terminal Z-DNA binding domain of 
an E3 orthologue from Yatapoxvirus had a helix-turn-helix (HTH) motif and three 
antiparallel b-sheets [33]. In comparison to N-terminal of Yatapoxvirus, the VACV E3 
proteins did not have a a/b architecture typical of Z-DNA binding protein family as per the 
predicted structure but solving the structure of E3 could provide an insight to the real 
structural configuration of the protein. The dsRNA binding C-terminal domain of E3 (amino 





Figure 7.2. Predicted secondary structure of VACV E3 protein.  
The prediction of the secondary structure was performed by ITASSER. The N-terminal 
consisted of coils and  a-helices whereas the C-terminal was predicted to be composed of 





The 3-D structure model of VACV E3 protein was also predicted by ITASSER. Five 
different models were predicted and were ranked based on their C-score. C-score is a 
confidence score for estimating the quality of predicted models by I-TASSER. It is calculated 
based on the significance of threading template alignments and the convergence parameters 
of the structure assembly simulations. C-score is typically in the range of [-5,2], where a C-
score of higher value signifies a model with a high confidence and vice-versa [87-89]. The 
estimated global accuracy of the model is also based on C-score and C-score > -1.5 indicates 
a model of correct global topology. In this study, the model with highest C-score of -1.68 
was selected (Fig. 7.3). 
  
              
 
Figure 7.3. Predicted 3D model of VACV E3 protein. The prediction of the 3D model was 
performed by I-TASSER.  
 
7.3. Conclusion 
Based on the above mentioned results, the structure of VACV E3 protein could 




scanning for the E3 double mutant has to be conducted by setting up various crystal screen 
conditions at different temperatures (room temperature and 4°C). Observation of no crystals 
in the crystal trays that was set up with three different screen kits at room temperature 
suggested the protein might not be at a saturation concentration which leads to crystal 
formation. Optimization of protein concentration and setting up crystal trays at different 
temperatures would be required for successfully solving the structure of E3 proteins. Crystal 
trays were also set up for PKR-KD and E3 complex but without much success. The weak 
interactions of PKR-KD and E3 could be a major drawback for attempting to solve the 




















CONCLUSIONS AND FUTURE WORK 
 
8.1. Conclusions 
VACV E3 proteins have been studied for more than 15 years which resulted in a 
lot of information regarding its functional and biological characteristics. Solving the 
structure of the protein is an important aspect of E3 which would impart a completeness 
in the overall knowledge of this protein. This study focused on understanding the 
mechanistic aspect of E3 proteins. Various surface mutations were conducted in an effort 
to reduce the inherent nature of E3 aggregation. Two mutants (R131A and F148A) were 
successfully expressed and purified to produce lower oligomeric state of E3 proteins but 
did not completely abrogate the problem of aggregation. Optimization of purification of 
these mutants led to a procedure that could potentially produce homogeneous dimeric 
proteins. An E3 double mutant (R131A I110A) showed the best results when purified and 
concentrated to a desired concentration for crystallization (Fig. 4.7). Unlike the single E3 
mutants that aggregate at higher concentration, the double mutant had better stability and 
were a likely candidate for crystallization screening process. Crystal screening was 
conducted with the E3 double mutant samples which were more than 95 percent pure, 
stable and homogeneous with various commercially available kits but the lack of crystals 




 setting up crystal trays at different temperatures are imperative for successfully solving the 
structure of E3 proteins. Produced early in the viral replication cycle, E3 protein is known for 
its host range function, suppression of cytokine expression, and inhibition of interferon 
(IFN)-induced antiviral activity [8-10]. E3 is known to downregulate PKR activity, thus 
inhibiting the host immune response [72].  
In the event of a viral infection, PKR, a kinase protein in the host cell undergoes 
activation and thus start a cascade of reactions that initiate immune response against the 
virus.  PKR exists as an inactive monomer in homeostasis but undergoes dimerization for its 
activation during viral infections. A study proposed an autoinhibition model for PKR 
activation where dsRNA produced by viruses during infections bind to the DRBD of PKR, 
thus inducing a conformation change which helps in dimerization of the protein [61-63]. 
Another study supported this autoinhibition model by proposing that PKR’s second DRBD 
interacts with residues within the insert region (residues 328-335) to mask PKR’s kinase 
domain [64]. Although it has been shown that dsRNA binding to DRBDs leads to PKR 
dimerization, evidence for a dsRNA independent mechanism also has been reported [65, 66]. 
A study conducted by Tan et al. found that PKR can dimerize in vivo and in vitro 
independently of the DRBDs and the dimerization is mediated by amino acid residues 244 to 
296 [67]. The second step of PKR activation is autophosphorylation which occurs 
simultaneously during dimerization. A study showed that a kinase dead PKR mutant K296R 
impaired PKR-KD dimerization, indicating that kinase domain dimerization promotes 
activation segment autophosphorylation of PKR, which in turn would stabilize dimerization 
[68]. Hence, it is considered that autophosphorylation and dimerization are mutually 




serine 51 position. The phosphorylated eIF2a inhibits the translation initiation process and 
thus reduce protein synthesis [49].  
VACV E3 protein inhibits the activation of PKR thus preventing the onset of immune 
response. An early study on vaccinia virus had reported an inhibitor of PKR 
autophosphorylation but the study did not specify the involvement of E3 proteins [74]. It was 
found in a study that the downregulation of host defense mechanisms correlated with the 
accumulation of E3 early in VACV infection [29, 73]. The mechanism of E3 inhibition of 
PKR activity has been speculated and different in vivo studies had demonstrated that E3 
inhibited the dimerization of PKR by forming an inactive heterodimer of E3-PKR [13, 75]. 
Although the effect of E3 on PKR has been established more than two decades ago, a 
breakdown of this process is yet to be determined. A recent study had shown that E3 protein 
does not require the dsRNA binding ability to perform their biological functions [14]. Hence, 
in this study we attempted to understand the complete mechanism of E3 inhibition of PKR 
activity and it was predicted that E3 and PKR proteins would interact with each other in the 
absence of their dsRNA binding capacities. Hence, E3 mutants (with no dsRNA binding 
ability) and only the kinase domain of PKR were used in this study to understand the 
mechanism of their interaction. Monomeric inactive PKR-KD and dimeric activated PKR-
KD were used in the assays to understand the difference in interaction with E3 protein.  
Based on the in vitro and in vivo binding assays conducted by Sharp et al., two 
regions on PKR were known to interact with VACV E3 protein. One of the binding region 
involved the DRBDs of PKR and the other overlapped the region of interaction with the 
substrate eIF2a and the pseudosubstrate VACV K3 protein [75]. This study demonstrated 




by forming nonfunctional heterodimers. In vitro pull down and binding assays in this study 
indicated a physical interaction between E3[R131A] mutant and monomeric PKR-KD (Fig. 
5.2, 5.4, 5.6). It was for the first time that the direct interaction of E3 and the catalytic 
domain of PKR has been demonstrated in vitro. Similar pull down and binding assays for 
dimeric PKR-KD demonstrated a lack of interaction between both proteins (Fig. 5.3, 5.5, 
5.7). These results indicated that E3 could bind to the catalytic domain of PKR when it is in 
an inactive monomeric state without the dsRNA binding ability of both proteins.  
In vitro kinase and autophosphorylation assays revealed the inhibitory effect of 
E3[R131A] mutant on the dimerization, autophosphorylation and substrate phosphorylation 
of PKR-KD proteins. It was detected that higher oligomers of E3 (10 to 12 E3 molecules) or 
high molecular weight aggregates did not have any effect on the PKR-KD activity in in vitro 
kinase and autophosphorylation assays. Dimeric or trimeric E3 fractions were used for the 
assays to ensure the inhibitory effects of E3 on PKR-KD activity. These criteria and 
conditions were followed for all the in vitro assays to remain consistent through-out. Based 
on these results, a model for the PKR-KD and E3 interaction mechanism was predicted (Fig. 
8.1). According to the model, E3 interacts with PKR-KD in two ways; first when E3 
encounters monomeric PKR-KD and second when it interacts with dimeric PKR-KD. The 
first mechanism works when a lower oligomeric state E3 protein physically binds to 
monomeric PKR-KD to inhibit it from undergoing autophosphorylation and thus preventing 
the cascade of reactions that follows to initiate the immune response. The second mechanism 
occurs when lower oligomeric state E3 proteins inhibit the activity of dimeric PKR-KD 
which are already activated due to dimerization. A weak interaction between these proteins 




have to be performed to understand the actual mechanism of E3 and dimeric PKR-KD 
interaction.   
 
 
Figure 8.1. Predicted model of the mechanism by which E3 interacts and inhibits PKR-KD 
activity.  
E3 inhibits PKR-KD by two mechanisms to ultimately continue regular protein synthesis 
during viral infection in host cells. Pathway A: E3 in a lower oligomeric state inhibits 
activation of monomeric PKR-KD protein by disrupting the dimerization process. This is 
achieved by direct physical interaction between E3 and PKR-KD. Pathway B: E3 in a lower 
oligomeric state inhibits already activated dimeric protein to regulate PKR-KD activity. A 
weak interaction between E3 and dimeric PKR-KD is suspected to be the method of 
regulation. 
 
The C-terminal domain of E3[R131A] mutant could not inhibit either monomeric or 
dimeric PKR-KD activity which was due to the absence of physical interactions between 
these proteins (Fig. 6.12). The N-terminal of E3 had an inhibitory effect only on the dimeric 
PKR-KD but a physical interaction between these proteins could not be established (Fig. 6.8, 
6.10, 6.11). A weak interaction between E3-N and dimeric PKR-KD that disrupts the PKR-
KD dimer could explain the inhibitory effect of E3-N protein. A previous in vivo study had 




dimerization in the absence of dsRNA binding by E3 [13]. In spite of the statement, the study 
failed to show experimental data supporting their arguments for interaction of E3 N-terminal 
with dimeric PKR-KD. A lack of physical interaction between these protein was explained as 
inconsistencies that could be due to the high off rate for this interaction [13]. Our in vitro 
data on E3 N-terminal and dimeric PKR-KD had similar annotations as the previous study. 
Surprisingly, when both N- and C-terminals of E3 were added in an equal molar ratio and 
used for in vitro kinase assay, no inhibition of eIF2a phosphorylation was observed for 
monomeric and dimeric PKR-KD (Fig. 6.14). The E3 N protein individually had inhibited 
the activity of GST-PKR-KD but remarkably this was not observed in case of the protein 
mixture. An explanation for this phenomenon could be that E3 C protein binds to E3 N in the 
protein mixture which makes the binding surface of E3 N interacting with dimeric PKR-KD 
inaccessible. This leads to no inhibition of GST-PKR-KD activity by E3 N as observed 
earlier. An in vitro interaction assay of E3N and E3C showed a possible protein-protein 
interaction between these proteins (Fig. 6.15). It was deduced from these results that both the 
N and C-terminals of E3 protein are required for interacting and inhibiting PKR-KD as 
mentioned in previous studies [13, 75].  
The double mutants of E3 (E3R131AI110A, E3R131AF159A) had a strong inhibitory 
effect on the activity of monomeric and dimeric PKR-KD (Fig. 6.17, 6.20). The inhibition 
was observed more in case of dimeric as compared to monomeric PKR-KD. 
E3[R131AI110A] protein had the maximum impact on PKR-KD activity as compared to 
single mutants and other constructs of E3 used in various in vitro kinase assays. This strong 




on E3 protein could structural alter the protein to enhance its binding ability to PKR-KD 
proteins as compared to other E3 constructs.  
It has always been suggested that PKR and E3 interact with each other with the aid of 
their dsRNA binding domains. In this study, we demonstrated that E3 mutants that have 
completely lost the ability to bind to dsRNA could interact with the catalytic domain of PKR 
and inhibit its’ activity. An in vitro kinase assay was developed to detect the effect of E3 
mutants on autophosphorylation of PKR-KD and phosphorylation of eIF2a. The 
consistencies and reproducibility of these assays validate the robustness of these assays. 
Overall, this in vitro study was the first time to demonstrate the novel mechanisms of E3 
inhibition of PKR-KD.  
 
8.2. Recommendations for future work  
Optimization of the crystallization screening with E3 double mutant 
(E3R131A/I110A) is an important effort required for solving the structure of E3 by x-ray 
crystallography. Obtaining crystals that would undergo diffraction when exposed to x-rays 
requires multiple optimization steps. It is important to optimize at every step of the process. 
Along with the E3[R131A/I110A] protein, other combinations of mutations could be tested 
for a stable E3 protein which could also be used for crystallization. This would increase the 
chances of obtaining an E3 protein crystal for structural analysis. An effort to obtain crystals 
of the PKR-KD and E3 complex was also made in this study. It was predicted that the E3 
proteins would make a stable complex with PKR-KD. The weak interactions between the two 
proteins became the main deterrent of crystal formation. An artificial linker between the two 




these types of unstable interactions, particularly where the interaction is weak and transient, 
by creating a covalent link between the proteins to form a stable protein–protein complex 
[90]. MHC class II molecules along with their antigenic peptides is an example of a protein-
protein interaction that was stabilized by these artificial linkers [90]. Following this method 
and solving the structure of the complex could explain the interactions between E3 and PKR 
protein in depth. This would also explain the interaction between E3 and dimeric PKR-KD 
and thus the mechanism of the E3 inhibiting the dimeric PKR-KD activity.  
VACV inhibits the immune response of a host cell by producing two critical host 
range proteins E3 and K3 early in the viral replication. The mechanism of inhibition of 
immune response is different in case of both the proteins. E3 binds to catalytic domain of 
PKR and inhibit the dimerization activation whereas K3 proteins have a limited sequence 
similarity to the N-terminal domain of eIF2a and are considered a pseudo-substrate for PKR 
proteins. A number of studies have shown that K3 inhibits phosphorylation of eIF2a by PKR 
both in-vitro and in-vivo [72, 86, 91]. A crystal structure of K3 protein have shown a direct 
interaction between the C-terminal of PKR and the region of interaction is an equivalent PKR 
recognition motif shared with eIF2a [86]. Binding assays with 35S labeled E3 and K3 
proteins with PKR have suggested that E3 binds to catalytic domain of PKR that is same or 
overlaps with the K3/eIF2a binding site [75]. These results could be further verified by 
performing competitive assays with E3, K3 and PKR-KD proteins. Structural analysis of E3 
and PKR complex would shed some light on the exact nature of interaction between the two 
proteins and would also provide information regarding the competitiveness for binding to a 




for generating a complete picture on E3 protein and this study has provided a solid base 
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Table. A.1. Mass spectrometric analysis of protein bands from SDS-PAGE gels for 












Figure A.1. Thermal shift analysis of E3 protein stability in different volatile organic  
solutions. The x-axis represents the increasing temperature during thermal shift assays 
whereas the y-axis corresponds to the first derivative of the fluorescence emission as a 
function of temperature (d[fluorescence]/dT). The melting temperature (Tm) is represented as 
the highest part of the curve. The solid red curve represents the Tm of E3[R131A] protein 






Figure A.2. Thermal shift analysis of E3 protein stability in different non-volatile 
organic  solutions. The x-axis represents the increasing temperature during thermal shift 
assays whereas the y-axis corresponds to the first derivative of the fluorescence emission as a 
function of temperature (d[fluorescence]/dT). The melting temperature (Tm) is represented as 
the highest part of the curve. The solid red curve represents the Tm of E3[R131A] protein 






Figure A.3. Thermal shift analysis of E3 protein stability in an osmolyte 
(Trimethylamine N-oxide dihydrate) solution. The x-axis represents the increasing 
temperature during thermal shift assays whereas the y-axis corresponds to the first derivative 
of the fluorescence emission as a function of temperature (d[fluorescence]/dT). The melting 
temperature (Tm) is represented as the highest part of the curve. The solid red curve 






Figure A.4. Thermal shift analysis of E3 protein stability in detergents. The x-axis 
represents the increasing temperature during thermal shift assays whereas the y-axis 
corresponds to the first derivative of the fluorescence emission as a function of temperature 
(d[fluorescence]/dT). The melting temperature (Tm) is represented as the highest part of the 







Figure A.5. Thermal shift analysis of E3 protein stability with amphiphiles. The x-axis 
represents the increasing temperature during thermal shift assays whereas the y-axis 
corresponds to the first derivative of the fluorescence emission as a function of temperature 
(d[fluorescence]/dT). The melting temperature (Tm) is represented as the highest part of the 








Figure A.6. Thermal shift analysis of E3 protein stability with nondetergent solutions. 
The x-axis represents the increasing temperature during thermal shift assays whereas the y-
axis corresponds to the first derivative of the fluorescence emission as a function of 
temperature (d[fluorescence]/dT). The melting temperature (Tm) is represented as the highest 
part of the curve. The solid red curve represents the Tm of E3[R131A] protein without any 







Figure A.7. Thermal shift analysis of E3 protein stability with polyols. The x-axis 
represents the increasing temperature during thermal shift assays whereas the y-axis 
corresponds to the first derivative of the fluorescence emission as a function of temperature 
(d[fluorescence]/dT). The melting temperature (Tm) is represented as the highest part of the 








Figure A.8. Thermal shift analysis of E3 protein stability with carbohydrates. The x-axis 
represents the increasing temperature during thermal shift assays whereas the y-axis 
corresponds to the first derivative of the fluorescence emission as a function of temperature 
(d[fluorescence]/dT). The melting temperature (Tm) is represented as the highest part of the 






Figure A.9. Thermal shift analysis of E3 protein stability with polymers. The x-axis 
represents the increasing temperature during thermal shift assays whereas the y-axis 
corresponds to the first derivative of the fluorescence emission as a function of temperature 
(d[fluorescence]/dT). The melting temperature (Tm) is represented as the highest part of the 






Figure A.10. Thermal shift analysis of E3 protein stability with a chelating agent 
(EDTA). The x-axis represents the increasing temperature during thermal shift assays 
whereas the y-axis corresponds to the first derivative of the fluorescence emission as a 
function of temperature (d[fluorescence]/dT). The melting temperature (Tm) is represented as 
the highest part of the curve. The solid red curve represents the Tm of E3[R131A] protein 








Figure A.11. Thermal shift analysis of E3 protein stability with reducing agents. The x-
axis represents the increasing temperature during thermal shift assays whereas the y-axis 
corresponds to the first derivative of the fluorescence emission as a function of temperature 
(d[fluorescence]/dT). The melting temperature (Tm) is represented as the highest part of the 






Figure A.12. Thermal shift analysis of E3 protein stability with co-factors (NADH and 
ATP). The x-axis represents the increasing temperature during thermal shift assays whereas 
the y-axis corresponds to the first derivative of the fluorescence emission as a function of 
temperature (d[fluorescence]/dT). The melting temperature (Tm) is represented as the highest 
part of the curve. The solid red curve represents the Tm of E3[R131A] protein without any 






Figure A.13. Thermal shift analysis of E3 protein stability with chaotropes. The x-axis 
represents the increasing temperature during thermal shift assays whereas the y-axis 
corresponds to the first derivative of the fluorescence emission as a function of temperature 
(d[fluorescence]/dT). The melting temperature (Tm) is represented as the highest part of the 







Figure A.14. Thermal shift analysis of E3 protein stability with polyamines. The x-axis 
represents the increasing temperature during thermal shift assays whereas the y-axis 
corresponds to the first derivative of the fluorescence emission as a function of temperature 
(d[fluorescence]/dT). The melting temperature (Tm) is represented as the highest part of the 






Figure A.15. Thermal shift analysis of E3 protein stability with linkers. The x-axis 
represents the increasing temperature during thermal shift assays whereas the y-axis 
corresponds to the first derivative of the fluorescence emission as a function of temperature 
(d[fluorescence]/dT). The melting temperature (Tm) is represented as the highest part of the 






Figure A.16. Thermal shift analysis of E3 protein stability with dissociating agents. The 
x-axis represents the increasing temperature during thermal shift assays whereas the y-axis 
corresponds to the first derivative of the fluorescence emission as a function of temperature 
(d[fluorescence]/dT). The melting temperature (Tm) is represented as the highest part of the 






Figure A.17. Thermal shift analysis of E3 protein stability with amino acid (L-proline). 
The x-axis represents the increasing temperature during thermal shift assays whereas the y-
axis corresponds to the first derivative of the fluorescence emission as a function of 
temperature (d[fluorescence]/dT). The melting temperature (Tm) is represented as the highest 
part of the curve. The solid red curve represents the Tm of E3[R131A] protein without any 








Figure A.18. Thermal shift analysis of E3 protein stability with multivalent solutions. 
The x-axis represents the increasing temperature during thermal shift assays whereas the y-
axis corresponds to the first derivative of the fluorescence emission as a function of 
temperature (d[fluorescence]/dT). The melting temperature (Tm) is represented as the highest 
part of the curve. The solid red curve represents the Tm of E3[R131A] protein without any 
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